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1. Introduction 
 
1.1. The immune system 
1.1.1. Innate and adaptive immunity 
The human immune system is a highly complex system consisting of many components 
which play an important role in the defense against the myriad potentially pathogenic 
mirco-organisms as well as in the rejection of malignant tumors. It is composed of the 
innate and adaptive immune system: innate immunity mediates a non-specific, immediate 
first-line defense whereas adaptive immunity is specialized and characterized by specific 
recognition and long-lasting protective immunity. 
The innate immunity consists of different mechanisms to protect the body from harmful 
micro-organisms. A first mechanic barrier is the surface epithelium. Macrophages and 
neutrophil granuloyctes are critical in the defense against both intracellular and 
extracellular bacteria as well as against fungi by phagocytosis of these micro-organisms. 
Furthermore, the acute phase response and the complement system opsonize pathogens for 
phagocytic uptake and have direct antimicrobial activities. Host cells infected by viruses or 
other intracellular pathogens as well as tumor cells can be eliminated by natural killer cells 
(NK cells). Pathogens are detected by germline-encoded conserved pathogen pattern 
receptors (PPRs) which recognize motifs called PAMPs (pathogen-associated molecular 
patterns) or by missing self recognition (Medzhitov 2007). In addition to the important role 
as first defense against micro-oranganisms, innate immune recognition is also critical for 
activation of the adaptive immune system.  
Adaptive immunity is divided in humoral immunity mediated by B cells and cellular 
immunity mediated by T cells. In contrast to innate immunity, the concept of enormous 
diversity of B and T cell receptor (BCR and TCR) repertoires is based on somatic 
recombination and gene rearrangement. Professional antigen-presenting cells (APC) such 
as dendritic cells (DC) link innate and adaptive immunity (Steinman and Hemmi 2006). As 
professional APC, DC are usually located in the skin and mucosal epithelia, the sites of 
contact with external environment. Immature (i)DC are highly phagocytic and take up 
microbial antigens in the periphery. After phagocytosis, DC migrate to T cell rich areas in 
lymph nodes where DC-maturation is induced by cytokines. Mature DC (mDC) process 
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antigens and present them via Major Histocompatibility Complex (MHC) class I and II 
molecules to T cells, thereby initiating the cellular immune response (Abbas and Janeway 
2000). The humoral part of adaptive immunity is characterized by secretion of antibodies. T 
cells expressing CD154 and T cell-derived cytokines control the division and 
differentiation of activated B cells into antibody-secreting plasma cells. Antibodies acting 
in different ways support the removal of pathogens by phagocytes via opsonization, 
activate the complement system, and inhibit the entrance of pathogens into cells via binding 
to pathogens. Plasma memory B cells are capable to mediate lifelong immunity against 
once encountered pathogens. 
 
1.1.2. The adaptive cellular immune response 
The adaptive cellular response is mediated by T lymphocytes. The majority of T cells is 
characterized by TCRs with αβ-heterodimers mainly represented in the lymphoid organs 
and responding to peptide antigens. Only a small subset of T cells which is located in the 
mucosal and epithelial barrier expresses TCRs with γ and δ chains recognizing lipid 
antigens. In 1974, Zinkernagel and Doherty discovered that the recognition of foreign 
protein antigens in combination with self-MHC by TCRs is essential for T cell activity 
(Zinkernagel and Doherty 1974; Zinkernagel and Doherty 1997). Antigens of intracellular 
origin are typically presented on MHC class I molecules activating cytotoxic T cells which 
express the co-receptor CD8 whereas extracellular antigens are presented after endocytosis 
on MHC class II molecules stimulating T helper cells characterized by the co-receptor 
CD4. However, extracellular antigens can be also presented on MHC class I molecules 
giving rise to a cytotoxic response via a mechanism which is called cross-presentation. Two 
independent signals are commonly acknowledged to be critical for the activation of naïve T 
cells: the peptide-MHC-complex (pMHC) has to be recognized by the TCR followed by the 
additional binding of co-stimulatory molecules. Most of activated CD4+ helper cells move 
to the site of infection mobilizing and activating other immune cells. However, some CD4+ 
T cells remain in the lymph node providing a cytokine environment which supports B cell 
functions (Campbell, Kim et al. 2001). CD4+ T cells are known to differentiate in one of 
many diverse subsets, depending on the kind of pathogens and the surrounding cytokines. 
Th1, Th2, Th17 and Treg are the most prominent CD4+ subsets. Th1 cells play an important 
role in inflammation processes and activate macrophages, NK cells and T cells via 
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interferon (IFN)-γ secretion whereas the most described function of Th2 cells is the 
recruitment of mast cells, basophil and eosinophil granulocytes by interleukins (IL) as IL-4, 
IL-13 and IL-25 as defense at mucosal and epithelial surfaces (Szabo, Sullivan et al. 2003; 
Voehringer, Reese et al. 2006). Th17 are amongst others able to activate neutrophils by 
secretion of IL-17, IL-6 and tumor necrosis factor (TNF), thereby regulating acute 
inflammation (Langrish, Chen et al. 2005; Mangan, Harrington et al. 2006). A further 
subset of CD4+ T cells is formed by naturally occurring and induced regulatory T cells 
(Tregs). Todays most prominent population of CD4+ Tregs are characterized by high 
expression of CD25 and the transcription factor Foxp3 and exert their regulatory function 
by suppression of other T cells as well as modulation of DC (Vignali, Collison et al. 2008; 
Josefowicz and Rudensky 2009). CD4+CD25+Foxp3+ Tregs are known to use different 
mechanisms to suppress responder T cells: the release of suppressive cytokines as IL-10, 
IL-35, and transforming growth factor (TGF)-β leads to inhibition of effector T-cell (Teff) 
differentiation and activation. Moreover, the consumption of IL-2 in competition with 
responder T cells limits Teff proliferation, and secreted or surface molecules as galectin-1 
can directly inhibit responder T cells (Shevach 2008). Furthermore, Tregs suppress the 
maturation of DC by LAG-3 binding to MHC class II and decrease co-stimulation by 
CTLA-4 interaction with CD80 or CD86 (Shevach 2008). Another described regulatory T-
cell subpopulation is represented by TCRαβ+CD4-CD8- double negative (DN) T cells 
(Zhang, Yang et al. 2000; Fischer, Voelkl et al. 2005). Murine DN T cells were already 
identified in 2000 to exhibit a strong immuneregulatory function (Zhang, Yang et al. 2000). 
Recently, our group could show that human DN T cells excert a very potent suppressive 
activity towards CD4+ and CD8+ T cells (unpublished data). 
CD8+ T cells are important players in the clearance of intracellularly infected cells and in 
the rejection of malignant tumors. Naïve CD8+ T cells can face different fates: In the case 
of steady state antigen recognition, peripheral tolerance in CD8+ T cells can result in the 
two distinct differentiation states, apoptosis and anergy. In both cases T cells generally fail 
to develop effector functions (Hernandez, Aung et al. 2001; Schwartz 2003). Under these 
circumstances, programmed death 1 (PD-1) is required for both, anergy and deletion of 
CD8+ T cells (Goldberg, Maris et al. 2007; Tsushima, Yao et al. 2007). The outcome seems 
to be largely dependent on the overall level of TCR signaling (Parish and Kaech 2009). 
High antigen levels typically cause anergy whereas lower antigen levels lead to apoptosis 
(Redmond, Marincek et al. 2005). Antigen-presentation by APC in the immunological 
context of infection activates CD8+ T cells which then will expand and differentiate into 
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effector and memory T cells. Effector CD8+ T cells, also called cytotoxic T lymphocytes 
(CTL), can clear infected cells by release of effector molecules as perforin and granzyme or 
by stimulation of cell surface bound molecules such as Fas. Furthermore, CTL produce 
high amounts of antiviral cytokines such as IFN-γ and TNF upon TCR ligation (Williams 
and Bevan 2007). Cytokines secreted by the innate immune system, in particular IL-12 and 
type 1 interferons, also promote CTL expansion (Cousens, Peterson et al. 1999; Mescher, 
Curtsinger et al. 2006). Of importance, in certain chronic infections CD8+ T cells fail to 
exert their normal effector functions such as IFN-γ, TNF and IL-2 production and 
cytotoxicity. Exhaustion, as this specific state of dysfunction is called, seems to be driven 
by up-regulation of a network of inhibitory receptors such as PD-1 and LAG-3 (Barber, 
Wherry et al. 2006; Blackburn, Shin et al. 2009). After successful clearance of the 
pathogens, the immune reaction is stopped by elimination of most of activated T cells by 
apoptosis (Hildeman, Zhu et al. 2002). However, a small percentage persists for a long 
period of time as memory T cells. This subpopulation has a unique ability for self-renewal 
and survival, and is therefore able to mediate fast and effective immune reactions at 
reinfections with the same pathogens once encountered. 
 
1.1.3. Interactions between T cells and antigen-presenting cells 
A rapid, flexible and dynamic immune system is required to protect the host. Although T 
cells need to be primed by DC, they represent a major force in eliminating pathogens which 
needs to be carefully regulated to avoid excessive immune reactions.  
This regulation can be mediated by interaction of molecules on the surface of APC like the 
C-type lectin DC-specific ICAM-3 grabbing non-integrin (DC-SIGN, also CD209). DC-
SIGN has a broad range of functions: it is an adhesion receptor responsible for clustering of 
naïve T cells through binding of intercellular adhesion molecule (ICAM)-3, interacts with 
ICAM-2 on endothelial cells to induce transendothelial migration and can function as 
antigen-receptor (Geijtenbeek, Krooshoop et al. 2000; Engering, Geijtenbeek et al. 2002; 
van Gisbergen, Paessens et al. 2005). The cellular interaction between DC-SIGN and 
ICAM-3 facilitates the formation of low-avidity lymphocyte functional-associated antigen 
1 (LFA-1) interaction with ICAM-1 on the DC as well as the screening of antigen-MHC 
repertoire (van Kooyk and Geijtenbeek 2002). The importance of ICAM-1 for effective 
CTL priming could be demonstrated by the fact that ICAM-1 deficient DC could not form 
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long-lasting contacts with CD8+ T cells resulting in reduced IFN-γ production in vitro and 
in vivo (Scholer, Hugues et al. 2008).When the TCR recognizes an antigen presented via 
MHC molecules, this binding between T cells and APC is getting stronger through high 
avidity LFA-1-ICAM-1 and CD2-LFA-3 interactions (McDowall, Leitinger et al. 1998; 
Bleijs, Geijtenbeek et al. 2001). TCR engagement is followed closely by the migration of 
LFA-1 from the central contact site to a more peripheral location, whereas the TCR 
complex is moved to the center of the immunological synapse forming the central 
supramolecular activation cluster (cSMAC) surrounded by the peripheral supramolecular 
activation cluster (pSMAC) (Monks, Freiberg et al. 1998; Bromley, Burack et al. 2001).  
The TCR is critical for antigen recognition and is always co-expressed with CD3 chains 
which are essential for the signal transduction into the cell via immunoreceptor tyrosine-
based activation motifs (ITAMs) (Irving and Weiss 1991; Wegener, Letourneur et al. 
1992). The TCR co-receptors CD4 and CD8 interact with conserved residues of MHC 
molecules and are bound to the protein tyrosine kinase lck at their cytoplasmic tails (Rudd 
1990). Upon engagement of the TCR with antigen-MHC complex, the co-receptor-lck 
complex comes into proximity of the CD3 ITAMs, thus starting the TCR signal cascade. As 
further required positive regulator for T cell activation, CD45 is one of the most abundant 
surface antigens on immune cells and characterized as transmembrane molecule with potent 
protein tyrosine phosphatase activity (Tonks, Diltz et al. 1991; Trowbridge and Thomas 
1994). After first TCR engagement, the cell is primed to respond to other activating stimuli, 
e.g. through the increased affinitiy as well as the higher avidity of integrins for the 
interaction with further APC.  
One very special feature of T-cell activation is that TCR engagement with pMHC-complex 
on its own is not sufficient for a proper T-cell response as mentioned above (Schwartz 
2003). In addition to TCR engagement as signal 1, T cells need also a signal 2 initiated by 
binding of one of several co-stimulatory receptors. This second signal transduces 
independent signals or enhances the signaling cascades initiated by the engagement of the 
TCR complex which is critical for T-cell proliferation and effector differentiation. The 
most physiologically relevant co-stimulatory receptor on T cells seems to be presented by 
the cell surface homodimer CD28 (Acuto and Michel 2003). Ligands of CD28 that are 
present on APC and belong to the B7 familiy are CD80 (B7-1) and CD86 (B7-2). They are 
up-regulated together with MHC molecules in presence of pathogens after signals of the 
innate immune system guaranteeing a better delivery of both important signals to T cells 
(Sharpe and Freeman 2002). Another member of the CD28 family is inducible co-
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stimulator (ICOS): ICOS expression on naïve T cells is low but increases after TCR 
stimulation (Hutloff, Dittrich et al. 1999; Yoshinaga, Whoriskey et al. 1999). In contrast to 
CD28, ICOS does not bind to B7-1 and B7-2, but to yet another member of the B7 family 
called ICOS ligand which is expressed more broadly than B7-1 and B7-2 (Coyle and 
Gutierrez-Ramos 2001). Both ICOS and CD28 activation leads to enhanced cytokine 
production by T cells but ICOS signaling does not up-regulate IL-2 expression. Instead, 
ICOS seems to play a more important role for T cell mediated B cell help, for Ig class 
switching as well as for formation of germinal centers (Coyle, Lehar et al. 2000). These 
small differences in the co-stimulatory outcome have important regulatory functions in 
orchestrating the immune response. In regard to the growth of T cells, IL-2 receptor 
signaling plays a major role in the regulation of proliferation. Prior to stimulation, naïve T 
cells express only a moderate affinity IL-2 receptor consisting of the β and γ chains. A third 
IL-2 receptor component, the α chain (CD25), is expressed upon TCR ligation resulting in 
an increased affinity for IL-2 (Minami, Kono et al. 1993).  
After the target cells are cleared, it is essential to stop proliferation and effector functions to 
prevent damage to uninfected tissue. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-
4) is a member of the CD28 family and is competitive to CD28 but has a much higher 
affinity to B7-1 and B7-2 than does CD28 by itself (Perkins, Wang et al. 1996). CTLA-4 is 
co-expressed on T cells after an initial T cell activation. Thus, high expression of CTLA-4 
on activated T cells prohibits the activating co-stimulatory receptors and impairs T-cell 
effector responses by prevention of further T-cell activation and by termination of 
additional expansion of antigen-specific clones (Carreno, Bennett et al. 2000). Another 
inhibitory molecule also belonging to the CD28 and CTLA-4 family is PD-1 (Zhang, 
Schwartz et al. 2004). PD-1 shows a much broader expression – namely on T cells, B cells, 
NK cells, activated monocytes as well as DC – as compared to CTLA-4 expression 
suggesting a widespread role in immune regulation (Greenwald, Freeman et al. 2005). PD-1 
is not expressed on resting T cells but is much like CTLA-4 inducibly expressed after 
activation, also emphasizing its immunoregulatory function (Nishimura, Agata et al. 1996). 
The known ligands of PD-1 are PD-L1 and PD-L2, which can both be found on DC. PD-1 
counteracts TCR signaling with greater inhibition at low levels of TCR stimulation. PD-1 
signaling is proposed to antagonize cell survival signals mediated by anti-apoptotic Bcl-xL, 
as well as effector differentiation mediated by CD28 and IL-2 (Keir, Butte et al. 2008). 
However, CD28 and IL-2 can overcome the negative impact of PD-1 signaling (Freeman, 
Long et al. 2000; Carter, Fouser et al. 2002). Along with CTLA-4 and PD-1, activation 
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induced cell death (AICD) is mediated by Fas (CD95)-Fas ligand interactions between T 
cells themselves. The components of the machinery necessary for AICD get up-regulated 
by TCR ligation, thereby making activated T cells more sensitive to AICD (Arnold, 
Brenner et al. 2006). Further death receptors called TNF-related apoptosis-inducing ligand 
(TRAIL)-R1 and TRAIL-R2 can be found on activated T cells whereas their ligand TRAIL 
is expressed on APC (Guicciardi and Gores 2009). In summary, interactions between DC and 
T cells play an important role in starting, increasing and finishing T-cell responses. 
 
 
 
Figure 1:  B7-CD28 superfamily costimulatory molecules.  This figure shows stimulatory (green stars) and 
inhibitory (red stars) receptors on T cells and their ligands on DC (Leitner, Grabmeier-Pfistershammer et al.) 
 
1.2. Tumor immunology 
Immune cells can be effective in controlling and eliminating malignant tumor cells. 
Nevertheless, chronic inflammation also can promote tumor growth because immune cells 
express many factors which favor tissue growth and renewal, angiogenesis and facilitate 
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metastasis (Coussens and Werb 2002). The fact that T cells can recognize tumor antigens is 
an important prerequisite for the rejection of tumor cells by T cells. Many factors playing a 
role in cellular tumor immunology have been identified: 1. the existence of tumor antigens 
by the use of T cells recognizing intact cancer cells, 2. tumor-specific T cells by cytokine 
release and lysis of the target cells and 3. immunogenic peptides by elution from cancer 
cells. In the case of melanoma, a prominent model self-antigen was identified and isolated 
after screening of melanoma cDNA libraries in 1994 as Melan-A, also called Mart-1 which 
is expressed on normal melanocytes and belongs to the family of melanocyte differentiation 
antigens (Coulie, Brichard et al. 1994; Kawakami, Eliyahu et al. 1994). The Mart-1 gene 
encodes for a 118 amino-acid protein expressed in 80% to 90% of melanoma as well as in 
cultured melanoma cell lines (Marincola, Hijazi et al. 1996). As highly immuno-dominant 
antigen, Mart-1 bearing HLA-A2 restricted epitopes, e.g. the naturally processed nonamer 
AAGIGILTV (Mart-1:27-35), is recognized by the majority of melanoma reactive T cells 
(Skipper, Gulden et al. 1999). Another well known antigen of the melanocyte 
differentiation family is gp100 which is involved in melanin synthesis bearing different T-
cell epitopes such as YLEPGPVTA (gp100:280-288), ITDQVPTSA (gp100:209-217) or 
VLYRYGSFSV (gp100: 476-485) (Cox, Skipper et al. 1994; Kawakami, Eliyahu et al. 
1995). Interestingly, high frequencies of Mart-1 reactive T cells are not only found in 
melanoma patients but also in healthy individuals. These T cells show differences in their 
phenotypes: in healthy individuals the naïve phenotype dominates whereas in melanoma 
patients T-cell populations are composed of both, naïve and effector T cells (Romero, 
Dunbar et al. 1998).  
Even though the immune system has many alternatives to fight against cancer, tumors have 
evolved mechanisms to evade the immune response. One problem for the immune system 
in elimination of tumor cells is the often immunosuppressive tumor microenvironment. T 
cells within melanoma and tumor-draining lymph nodes were shown to be functional 
impaired, but not the T cells of peripheral blood (Zippelius, Batard et al. 2004). Expression 
of arginase, nitric oxide synthetase or indoleamine-2,3-dioxygenase by human solid tumors 
have been demonstrated to mediate suppressive effects towards immune cells (Munn, 
Sharma et al. 2004; Bronte, Kasic et al. 2005). To enhance tumor-specific immune 
response, different strategies were evaluated in clinical trials to enhance tumor immunity. 
Many therapies aim for T-cell activation and expansion by administration of recombinant 
IL-2 and prevention of T-cell exhaustion by administration of anti-CTLA-4 blocking 
antibody (Rosenberg, Yang et al. 1994; Attia, Phan et al. 2005). Other approaches have 
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focused on active immunization using peptide, protein or recombinant viral cancer vaccines 
(Eder, Kantoff et al. 2000; Slingluff, Yamshchikov et al. 2001). Immunization with 
multiple peptides was applied to circumvent the escape of antigen-loss variants in therapies 
targeting just one single peptide (Valmori, Dutoit et al. 2003). Although an expansion of T 
cells could be observed in these trials, only a minority of patients showed clinical 
responses.  
The adoptive transfer of tumor-reactive T cells seems to be another promising therapeutic 
option for cancer patients. Autologous CD8+ T cells as potent effector cells can be activated 
and expanded ex vivo to large numbers with the aim of being transferred back into the 
patients. The combination of lympho-depletion followed by administration of antigen-
specific T cells in combination with recombinant IL-2 provided strong evidence that 
antigen-specific immunotherapies can result in cancer regression when appropriate 
treatment and host factors are combined. However, various factors as high levels of tumor 
infiltrating Tregs, NKT cells and CD11b+Gr+ myeloid suppressor cells have been shown to 
be unfavorable for efficient CTL responses (Terabe, Matsui et al. 2000; Curiel, Coukos et 
al. 2004; Makarenkova, Bansal et al. 2006). Other studies showed that terminally 
differentiated CD8+ T cells are less effective in vivo than T cells in an early stage of 
differentiation. Early effector CD8+ T cells also express lower levels of pro-apoptotic and 
higher levels of anti-apoptotic molecules and co-stimulatory CD28 (Gattinoni, Klebanoff et 
al. 2005). Furthermore, tumor infiltrating lymphocytes (TILs) with the highest CD28 
expression revealed the longest persistence after adoptive transfer (Powell, Dudley et al. 
2005). Moreover, expression of pro-inflammatory cytokines such as IFN-γ are essential to 
overcome effects of other immune-inhibitory factors such as TGF-β and IL-10, or receptors 
expressed in T cells such as CTLA-4 and PD-1 that act to limit anti-tumor responses (Wahl, 
Wen et al. 2006).  
Another therapeutic approach is based on the administration of antibodies to induce 
antibody dependent cellular cytotoxicity (ADCC) as well as complement activation. 
Rituximab, an antibody binding CD20, has shown effective anti-cancer activity against B 
cell lymphoma (Held, Poschel et al. 2006). Recently, bi-specific antibodies for functionally 
connecting target cells with effector cells play a promising role in the treatment against 
cancer (Agrawal, Garg et al. 2010; Thakur and Lum 2010). 
Despite the existence of functional immune responses, tumors can dodge the immune 
system evolving so called immune escape mechanisms. Tumor cells carrying mutations 
which lead to the loss of recognition by T cells e.g. by loss of the human leukocyte antigen 
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(HLA) I expression after β-2-microglobulin (β2m) mutation or deletion can selectively 
grow out (Restifo, Esquivel et al. 1993). In theory, NK cells should be able to recognize 
these cells, as they can act independently of HLA I expression. NK cells express activating 
receptors such as NKG2D which bind to stress-induced ligands (MICA, MICB) which are 
up-regulated in a variety of tumors (Gonzalez, Groh et al. 2006). One possible explanation 
to why NK cells do not destroy the tumor cells could be because NK cells are only rapidly 
activated in the presence of IL-12, IL-2, and type 1 interferons. Those cytokines are usually 
released under conditions of microbial infections, but not in a pathogen-free “sterile” 
environment as found in the majority of malignant tumors. Moreover, various tumor cells 
express cFLIP, an inhibitor of caspase-8, rendering those tumors resistant to receptor-
mediated apoptosis (Rippo, Moretti et al. 2004).  
Another obstacle for an effective T-cell mediated tumor response is the absence of co-
stimulatory molecules such as CD80, CD86, and CD40 on tumor cells leading to T-cell 
anergy. Next, immunosuppressive cytokines are often found in the serum of cancer 
patients. One important cytokine seems to be represented by vascular endothelial growth 
factor (VEGF) which is produced by most tumors and inhibits DC differentiation and 
maturation (Gabrilovich, Ishida et al. 1998). One study showed that increased plasma levels 
of VEGF correlated with a decreased number of mature (m)DC in tumor patients (Almand, 
Resser et al. 2000). Furthermore, elevated IL-10 levels were detected in cancer patients’ 
sera (Knauf, Ehlers et al. 1995; Fortis, Foppoli et al. 1996). IL-10 is known to be secreted 
by tumor cells and may protect them from CTL by downregulation of HLA I, HLA II, or 
ICAM-1 molecules.  
Expression of death receptor ligands such as FasL on tumor cells is known to be another 
immune escape mechanism, leading to apoptosis in Fas+ (CD95) susceptible target cells 
like activated T cells (Griffith, Brunner et al. 1995). PD-L1 is quite likely to have an 
important role in the evasion of tumor cells as its expression on tumors strongly correlates 
with the survival of patients (Blank and Mackensen 2007). Recently also trogocytosis was 
observed to play a role in immune evasion of tumors via shaving of target molecules or the 
transfer of multidrug-resistance (MDR) proteins as described later (Beum, Mack et al. 
2008; Rafii, Mirshahi et al. 2008). In summary, inhibitory cytokines and molecules, Tregs 
and the transfer of target molecules play an important role in the limitation of anti-tumor 
immune responses and the failure of cancer immunotherapy and limit immune responses. 
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1.3. Cell-to-cell communication via intercellular exchange of proteins, 
cytokines and chemokines 
Transcriptome as well as proteome are continually shared between interacting cells. 
Lymphocytes form cell-to-cell-connections during their circulation through the body which 
is critical for the immune response (Rechavi, Goldstein et al. 2009). In addition to 
interaction between immune cells, individual immune cells interact tightly with target cells 
in their environment in an antigen-dependent or –independent manner. During these 
interactions, connections such as nanotubes, gap junctions, “pores” and plasma membrane 
bridges are formed (Joly and Hudrisier 2003; Bopp, Becker et al. 2007; Davis 2007; 
Rechavi, Goldstein et al. 2007). These tight contacts facilitate the exchange of surface 
molecules between interacting cells (Davis 2007; Rechavi, Goldstein et al. 2009). 
Exosomes, nanotubes, and trogocytosis are the three best described mechanisms for cells to 
exchange cell components (Figure 2).  
 
 
Figure 2: Intercellular exchange via trogocytosis, exosomal protein transport and shuttle of proteins 
through nanotubes.  (Rechavi, Goldstein et al. 2009) 
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1.3.1. Exosomes and microvesicles 
One mechanism for intercellular exchange is the release and subsequent uptake of 
exosomes. Exosomes are enclosed membrane bodies with a size of 50 to 90 nm. Local 
disruption is known to result in membrane blebbing, thus interactions between the plasma 
membrane and the underlying cytoskeleton is important for the release of these membrane 
vesicles (Hudrisier and Bongrand 2002). This seems to be a quite common mechanism 
since many immune cells use this strategy of exchange of proteins as well as RNA, 
especially DC, T cells, and B cells (Raposo, Nijman et al. 1996; Zitvogel, Regnault et al. 
1998; Denzer, van Eijk et al. 2000; Fritzsching, Schwer et al. 2002; Andre, Chaput et al. 
2004). The release of exosomes can occur spontaneously or can be induced: Epstein-Barr 
Virus (EBV) transformed B cells, DC, macrophages, as well as tumor cell lines 
constitutively secret exosomes in vitro, while T and B cells release exosomes only upon 
activation (Peters, Geuze et al. 1989; Raposo, Nijman et al. 1996; Zitvogel, Regnault et al. 
1998; Blanchard, Lankar et al. 2002; Bhatnagar, Shinagawa et al. 2007; Arita, Baba et al. 
2008). iDC from mice show immediate increases in secretion of exosomes after interaction 
with antigen-specific T-cell clones, thus proposing a T-cell derived stimulus for induction 
of exosome secretion (Buschow, Nolte-'t Hoen et al. 2009). Tumor cells revealed an 
increased release of exosome-like membrane vesicles after radiation and induction of 
senescence (Yu, Harris et al. 2006; Lehmann, Paine et al. 2008). Some proteins such as 
p53, diacylglycerol kinase α as well as brefeldin A-inhibited guanine-nucleotide exchange 
protein 2 (BIG2) are known to play a critical role for the induction of secreted exosomes 
and exosome-like vesicles (Alonso, Rodriguez et al. 2005; Yu, Harris et al. 2006; Islam, 
Shen et al. 2007).  
Once secreted, exosomes can interact with recipient cells in many different manners. 
Adhesion via lipids is known as well as ligand-receptor interactions, internalization of the 
exosomes into endocytic compartments and fusion of the vesicles with the plasma 
membrane (Thery, Ostrowski et al. 2009). Blocking adhesion molecules by inhibitory 
antibodies resulted in reduced exosome-capture in co-cultures of DC with exosomes 
(Morelli, Larregina et al. 2004). In particular ICAM-1 on exosomes has been shown to play 
a role in the uptake by CD8+ DC expressing LFA-1 and by activated T cells in mice 
(Segura, Guerin et al. 2007; Nolte-'t Hoen, Buschow et al. 2009). This mechanism may be 
important for the dissemination of ICAM-1 expressing HIV virions (Fortin, Cantin et al. 
1998). Since murine exosomes and microvesicles have been shown to carry exposed 
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phosphatidylserine (PS) on their surface, PS receptors may be an alternative way for the 
uptake of exosomes (Miyanishi, Tada et al. 2007).  
The regular occurrence of exosomal exchange by numerous cells leads to the question of 
the potential function of exosomal exchange. A number of studies revealed that exosomes 
could play a pivotal role in antigen presentation (Tamai, Tanaka et al. 2010). Secreted 
membrane vesicles can carry both antigenic material and pMHC complexes (Thery, Duban 
et al. 2002). Exosomes purified from cultured tumor cell lines or from malignant ascites 
contain tumor antigens and can induce T-cell activation in the presence of recipient’s DC 
(Wolfers, Lozier et al. 2001; Andre, Schartz et al. 2002). Moreover, tumor-derived 
exosomes were characterized bearing transmembrane proteins such as EGFR2 or 
endosomal proteins such as Mart-1 and gp100. Macrophages infected by Mycobaterium sp. 
release exosomes containing pathogen-derived antigens (Giri and Schorey 2008); not only 
bacterial, but also virus antigens are transferred from endothelial cells infected with 
cytomegalovirus to DC via exosomes (Walker, Maier et al. 2009). Furthermore, exosomes 
also display preformed pMHC complexes. APC-derived exosomes carry large amounts of 
MHC class II molecules since they originate from the late endocytic compartments where 
MHC class II molecules are also located. APC-derived exosomes have been shown to 
activate human T-cell clones and lines as well as pre-activated murine CD4+ T cells without 
DC help (Raposo, Nijman et al. 1996; Admyre, Johansson et al. 2006; Muntasell, Berger et 
al. 2007). However, for activation of murine naïve CD4+ T cells, exosomes need to be 
captured by recipient DC first (Thery, Duban et al. 2002; Segura, Nicco et al. 2005).  
Exosomes can not only modulate immune responses by presenting antigens and MHC 
molecules but also by further stimulatory or inhibitory molecules. There are reports on 
CD95 ligand (CD95L, also FasL) or galectin 9 bearing microvesicles derived from tumor 
cell lines or tumor-bearing patients, that are capable of inducing T-cell apoptosis in vitro 
(Andreola, Rivoltini et al. 2002; Huber, Fais et al. 2005; Klibi, Niki et al. 2009). Tumor-
derived exosomes carrying transforming TGF-β have been shown to promote Treg function 
and impair NK-cell activity (Clayton, Mitchell et al. 2007). Not only APC and tumor cells, 
but also activated T cells secrete exosomes bearing CD95L which can induce apoptosis of 
bystander T cells (Monleon, Martinez-Lorenzo et al. 2001). Several studies showed that 
vesicle secretion by human tumors was described to inhibit anti-tumor immune responses 
thus proposing exosomes as a mechanism of immune escape (Taylor and Gercel-Taylor 
2005; Clayton, Mitchell et al. 2007; Huber, Filipazzi et al. 2008). 
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Besides immune inhibitory functions also immune-stimulatory properties have been 
reported for secreted vesicles. Pro-inflammatory exosomes released by macrophages 
infected by Mycoplsama sp. can induce polyclonal stimulation of T and B cells as well as 
secretion of pro-inflammatory cytokines, if the exosomes contain pathogen-derived pro-
inflammatory molecular determinants (Bhatnagar and Schorey 2007; Bhatnagar, Shinagawa 
et al. 2007; Quah and O'Neill 2007). A quite broad immune response can be triggered by 
microvesicles released by thrombin-activated platelets: they activate monocytes to secrete 
pro-inflammatory cytokines and stimulate proliferation, survival, and chemotaxis of other 
hematopoietic cells (Baj-Krzyworzeka, Majka et al. 2002; Baj-Krzyworzeka, Szatanek et 
al. 2007). The stimulatory capacity of tumor-derived exosomes observed in vitro has 
opened the field to investigate exosomes as a new immunotherapeutic strategy against 
cancer. Two phase I clinical trials have been performed in patients with advanced 
melanoma and non-small cell lung carcinoma using exosomes (Escudier, Dorval et al. 
2005; Morse, Garst et al. 2005). Data demonstrate that this novel immunotherapy is safe 
and can induce at least transient stabilization in 3 out of 6 patients in the melanoma trial 
and in 3 out of 9 patients in the lung carcinoma trial. 
 
1.3.2. Nanotubes 
Intercellular exchange of proteins through membrane tubes between cells provides another 
possible mechanism of cell-surface protein transfer between cells. Rustom et al. were one 
of the first describing the connections as membranous “tunneling nanotubes” (TNT) 
between rat pheochromocytoma PC12 cells (Rustom, Saffrich et al. 2004). These 
membrane bridges were also observed between human immune cells such as T cells, EBV-
transformed B cells, primary macrophages, and NK cells, as well as DC (Stinchcombe, 
Bossi et al. 2001; Onfelt, Nedvetzki et al. 2004; Watkins and Salter 2005). Nanotubes of 
human immune cells have been described to contain F-actin and to form an average length 
of about 20 µm and a diameter of 180 – 380 nm regarding nanotubes between T cells 
(Gurke, Barroso et al. 2008; Sowinski, Jolly et al. 2008). Characterizing the phenotype of 
nanotubes, three kinds of nanotubes were described as summarized by Gurke et al. (Gurke, 
Barroso et al. 2008). 
The one form of nanotubes is presented by membrane bridges forming uninterrupted TNT 
between cells and enabling the transport of organelles like endocytic vesicles or 
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mitochondria unidirectionally by an antigen-independent mechanism, as shown for DC and 
the human acute monocytic leukemia cell line THP-1 (Watkins and Salter 2005). Other 
nanotubular bridges between cells reveal a junctional border where distinct viral particles 
can be transported either at the surface of the nanotube by a receptor-dependent mechanism 
or inside the cellular nanotube by an actin-dependent mechanism (La Boissiere, Izeta et al. 
2004; Sowinski, Jolly et al. 2008). This mechanism has been described to play an important 
role in the spreading of HIV and herpes simplex virus. The third type of cellular nanotubes 
can extend in direction of the target cell, probably due to chemotaxis, but has no 
physiologic contact side. This kind of nanotubes may play a role in the delivery of secreted 
signaling molecules to the target cell and subsequent uptake by a receptor-mediated 
endocytosis. Onfelt et al. demonstrated that endosomes and lysosomes are transported 
between macrophages by TNT, thus showing the immunological relevance (Onfelt, 
Nedvetzki et al. 2006). Moreover, the transfer via membrane nanotubes can enable cross 
presentation of antigen or MHC class II-rich vesicles (Peters, Raposo et al. 1995). Thus, the 
transport of antigenic signals between myeloid cells demonstrates the immunological 
communication mediated by nanotubes (Watkins and Salter 2005). Furthermore, nanotubes 
have been shown to enhance the cytotoxicity of NK cells for lysis of their target cells 
(Chauveau, Aucher et al.). Despite many in vitro data, the in vivo relevance of nanotubes 
remains still unclear. 
 
1.3.3. Trogocytosis 
In 1973, there was a first report on a phenomenon of direct transfer of protein molecules to 
the surface of another cell (Bona, Robineaux et al. 1973). In 2002, this process was termed 
trogocytosis by Hudrisier and colleagues (Hudrisier and Bongrand 2002). Trogocytosis is 
derived from the ancient greek word “trogo” what means as much as “to nibble” or “to 
gnaw” (Joly and Hudrisier 2003). Trogocytosis was then defined as intercellular transfer of 
membrane patches containing membrane-anchored proteins from a presenting cell to a 
lymphocyte (Hudrisier and Bongrand 2002). By now, the term “trogocytosis” is used less 
rigorously and refers to the cell-to-cell contact dependent exchange of plasma membrane 
and surface molecules between cells. In contrast to exosomes and nanotubes, trogocytosis 
allows rapid transfer of intact cell-surface proteins between cells in contact with one 
another (Davis 2007). Trogocytosis has been described for a wide range of immune cells 
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such as T cells, NK cells, DC, B cells, monocytes and even tumor cells. Nevertheless, the 
fundamental principles of trogocytosis and its physiological relevance are not yet clear. 
Most of the data regarding trogocytosis were generated in mouse models. Of importance, 
Huang and colleagues reported that murine antigen-specific CD8+ T cells capture pMHC 
class I complexes from APC after antigen-recognition, rendering them sensitive to peptide-
specific lysis by neighboring T cells (fratricide) (Huang, Yang et al. 1999). CD4+ T cells 
can not only capture pMHC class II complexes from APC with cognate antigen but also co-
stimulatory molecules such as CD80 and CD86 (Sabzevari, Kantor et al. 2001; Tsang, Chai 
et al. 2003; Mostbock, Catalfamo et al. 2007). Capture of membrane components by CD8+ 
T cells not only occurs in vitro but has been also described in vivo in mouse models (Riond, 
Elhmouzi et al. 2007). Furthermore, human CD4+ T cells have been shown to acquire co-
stimulatory CD80 after antigen-specific recognition (Tatari-Calderone, Semnani et al. 
2002; Game, Rogers et al. 2005). During transendothelial migration human T cells grab 
adhesion molecules such as CD31, CD49b, CD54, CD61 and CD62E (Brezinschek, 
Oppenheimer-Marks et al. 1999). Of interest, the transfer of membrane components occurs 
bidirectional during the interaction between T cells and DC (Busch, Quast et al. 2008). In 
addition, activated murine B cells transfer antigen-specific BCR to bystander B cells both, 
in vitro and in vivo, simultaneously with the transfer of membrane fragments (Quah, 
Barlow et al. 2008). This process is amplified by the interaction of the BCR with antigen 
and could play a role in increasing the effective APC pool. Of interest, proteins anchored or 
recruited to cytoplasmic face of the plasma membrane are more efficiently transferred than 
those at the luminal side of the cell (Daubeuf, Aucher et al.).  
Not only T cells, B cells, and DC but also NK cells can acquire membrane molecules via 
trogocytosis. Both human T cells and activated NK cells can temporary gain suppressive 
function after uptake of inhibitory HLA-G molecules from target cells (Caumartin, Favier 
et al. 2007; LeMaoult, Caumartin et al. 2007). An immediate switch from effector to 
regulatory function, caused by HLA-G acquisition, has been shown for CD4+ T cells which 
no longer responded to stimulation as well as for NK cells which transiently stopped both 
proliferating and being cytotoxic. Monocytes are also able to take up HLA-G by 
trogocytosis but seemingly without functional consequences (HoWangYin, Alegre et al.). 
This may be due to the fact that HLA-G disappears quickly from the surface of monocytes 
and is therefore not able to inhibit on-going T-cell proliferation or cytokine production. In 
contrast to acquisition of suppressive functions, NK cells also acquire NKG2D activating 
MHC Class I-related Chain A (MICA) from target tumor cells, thus triggering NK cell 
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degranulation after NK-NK cell interaction (McCann, Eissmann et al. 2007). In addition, 
tumor-experienced T cells were shown to acquire MICA supporting NK-cell effector 
function (Domaica, Fuertes et al. 2009). Trogocytosis not only influences NK cells in their 
functional outcome, but NK cells can also become sensitive to EBV infection after uptake 
of CD21 from EBV infected B lymphocytes (Tabiasco, Vercellone et al. 2003).  
In a clinical study, isolated stromal cells were observed to confer chemoresistance to 
epithelial ovarian cancer cells by trogocytosis of multi-drug resistance proteins (Rafii, 
Mirshahi et al. 2008). Moreover, treatment of CLL patients with rituximab (RTX) leads to 
the formation of a CD20-RTX complex on target B cells (Beum, Mack et al. 2008). After 
RTX administration, circulating B cells revealed an essential loss of the target antigen 
CD20 on their surface. This may be a consequence of trogocytosis, as in vitro data show 
that RTX-CD20 complexes are transferred from B cells to THP-1 monocytes and PBMC 
via Fcγ receptor-mediated trogocytosis. These two cases show that trogocytosis can have 
serious implications in cancer immunotherapies.  
In contrast, trogocytosis may not only inhibit but also facilitate anti-tumoral 
immunotherapies. It was described that trogocytosis allows detection and isolation of 
tumor-specific functional CTL endowed with high functional avidity which in turn may be 
useful in the clinical application of adoptive immunotherapy (Machlenkin, Uzana et al. 
2008). In addition, trogocytosis also facilitates the identification and quantification of 
pathogen-specific T cells without the need of identifying specific epitopes. These cases 
suggest that trogocytosis has implications for cancer immunotherapies while the 
physiological relevance of trogocytosis is still under debate.  
In summary, trogocytosis can be a double-edged sword of immunological outcomes: First, 
trogocytosis can stimulate and increase immune responses by augmenting cytokine 
secretion, offering co-stimulatory signals or increasing the pool of APC. Second, 
trogocytosis may induce anergy, turn effector cells into regulatory cells or may even cause 
fratricide of effector cells. Third, tumors can escape the immune system by acquisition of 
multi-drug resistance proteins or by loss of the target antigen. Taken together, trogocytosis 
is a widespread phenomenon in immune cells with diverse immunological and pathological 
consequences (Ahmed, Munegowda et al. 2008). A better understanding of the transfer 
process may help to translate this knowledge into therapeutic options in the near future.   
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1.4. Goals of this study 
Trogocytosis is a common way of immune cells to exchange cell components. This 
phenomenon is well examined for mouse cells but not much data exist about the transfer 
onto human T cells. This study focuses on trogocytosis of human antigen-specific T cells,  
especially CD8+ cytotoxic T cells. The goals of this study were to analyze which cell 
components are transferred from antigen-pulsed DC but also from antigen-presenting tumor 
cells onto human T cells via trogocytosis. Further investigations aimed for the 
characterization and for the underlying mechanism of the antigen-specific trogocytosis 
process. Therefore, factors as kinetics and cell-to-cell contact dependency have been 
evaluated. By blocking experiments, diverse components playing a role in the T cell 
interaction with DC and in T-cell activation have been tested for their relevance in the 
transfer process. Of importance, also functional consequences of trogocytosis was one 
major focus of these investigations.    
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2. Material and Methods 
 
2.1. Material  
2.1.1. Media, buffer and solutions 
AB-Serum, human: PAN Biotech, Aidenbach 
Annexin Binding Buffer: Becton Dickinson (BD), Heidelberg 
Cytofix fixation buffer: BD, Heidelberg 
DC-medium (B´): standard media with 10% FCS 
Dimethyl sulfoxide (DMSO): Sigma-Aldrich, Steinheim 
Dilution C (DilC) for PKH staining: Sigma-Aldrich, Steinheim 
FACSclean: BD, Heidelberg 
FACSflow: BD, Heidelberg 
FACSrinse: BD, Heidelberg 
Freezing medium: 90% fetal calf serum with 10% dimethyl sulfoxide 
FACS wash buffer: PBS  
FCS (fetal calf serum): PAA, Linz (Austria) 
FCS containing medium (B´): standard medium with 10% FCS 
Hank´s balanced salt solution (1x): PAA, Linz (Austria) 
HSA (human serum albumin): Baxter, Unterschleißheim 
Lymphocyte separation reagent (Pancoll): PAN Biotech, Aidenbach 
MACS-buffer: PBS + 2mM EDTA (Sigma-Aldrich, Steinheim) + 0.5% HSA  
Optimem: Gibco/Invitrogen, Karlsruhe  
Paraformaldehyde-solution: Sigma-Adlrich 
PBS (Phosphate buffered saline): Gibco/Invitrogen, Karlsruhe 
Standard medium (serum free) (M´): 500mL RPMI containing phenol red (PAN Biotech, 
Aidenbach) with adjuvants: 200mmol/L L-glutamine (Gibco/Invitrogen, Karlsruhe), 2mL 
vitamins (PAN Biotech, Aidenbach), 5mL non-essential amino acids (PAN Biotech, 
Aidenbach), 100mmol/L sodium pyruvate (PAN Biotech, Aidenbach), 40U/mL penicillin 
(Gibco/Invitrogen, Karlsruhe), 40µg/mL streptomycin (Gibco/Invitrogen, Karlsruhe), 
50µmol/L β-mercaptoethanol (Gibco/Invitrogen, Karlsruhe) 
T-cell medium (A´): standard medium + 10% AB serum  
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T-cell stimulation medium (A´TF): standard medium + 10% AB serum + TCGF (T cell 
growth factor; cytokine enriched supernatant described before in (Mackensen, Carcelain et 
al. 1994)) 
Tumor-cell medium (B´): standard medium + 10% FCS 
 
2.1.2 HLA-A2-binding peptides 
Peptide Aminoacid-sequence Solution Manufacturer 
Mart-1 
(Melan-A) 
ELAGIGILTV M´ 20% DMSO Calbiochem, 
Läufelfingen (Schweiz) 
gp100 ITDQVPFSV M´ 5% DMSO Bachem, Heidelberg 
 
 
2.1.3 Peptide-MHC-tetramers 
 
Tetramer Conjuagation Manufacturer 
Melan-A PE Beckman Coulter, Krefeld 
gp100 PE Beckman Coulter, Krefeld 
 
2.1.4. Antibodies 
The following monoclonal antibodies conjugated with fluorochromes were used for 
detection of surface antigens: 
Specificity Isotype Clone Source Conjugation Manufacturer 
CD3 IgG1 SK7 mouse PerCP BD, Heidelberg 
CD3 IgG1 SK7 mouse PE-Cy7 BD, Heidelberg 
CD4 IgG1 SK3 mouse PerCP BD, Heidelberg 
CD4 IgG1 SK3 mouse PE-Cy7 BD, Heidelberg 
CD8 IgG1 SK1 mouse PerCP BD, Heidelberg 
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Specificity Isotype Clone Source Conjugation Manufacturer 
CD8 IgG1 RPA-T8 mouse APC BD, Heidelberg 
CD8 IgG1 SK1 mouse APC-H7 BD, Heidelberg 
CD14 IgG2b MoP9 mouse PerCP BD, Heidelberg 
CD16 IgG1 3G8 mouse PE BD, Heidelberg 
CD19 IgG1 SJ25-C1 
 
mouse APC Caltag, 
Buckingham. UK 
CD25 IgG1 2A3 mouse PE BD, Heidelberg 
CD25 IgG1 2A3 mouse PE-Cy7 BD, Heidelberg 
CD56 IgG2b NACM1
6.2 
 
mouse FITC BD, Heidelberg 
CD69 IgG2a CH/4 mouse PE Caltag, 
Buckingham. UK 
CD80 IgM BB1 mouse FITC BD, Heidelberg 
CD80 IgG1 L307.4 mouse PE BD, Heidelberg 
CD83 IgG1k HB15e mouse APC BD, Heidelberg 
CD86 IgG1 2331 mouse FITC BD, Heidelberg 
CD107a IgG1 H4A3 mouse PE eBioscience, 
Frankfurt 
CD137 IgG1 4B4-1 mouse APC BD,Heidelberg 
CD209 IgG2b 120507 mouse APC R&D Systems, 
Wiesbaden-
Nordenstadt 
HLA-ABC IgG1 G46-2.6 mouse PE BD,Heidelberg 
HLA-DR IgG2a L243 mouse PerCP BD, Heidelberg 
MCSP IgG1 7.1 mouse PE Beckman Coulter 
PD-1 IgG1k MIH4 mouse APC eBioscience, 
Frankfurt 
PDL-1 (B7-
H1) 
IgG1 MIH1 mouse PE eBioscience, 
Frankfurt 
PDL-1 (B7-
H1) 
IgG1 MIH1 mouse Biotin eBioscience, 
Frankfurt 
PD-L2 IgG1 MIH18 mouse PE eBioscience 
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Specificity Isotype Clone Source Conjugation Manufacturer 
TCRαβ IgG2b BW242/
412 
mouse PE Miltenyi, 
Bergisch-
Gladbach 
 
Isotype control staining was carried out with the following immunoglobulins conjugated 
with fluorochromes: 
Isotype Clone Source Conjugation Manufacturer 
IgG1 X40 mouse FITC BD, Heidelberg 
IgG1 X40 mouse PE BD, Heidelberg 
IgG1 X40 mouse APC BD, Heidelberg 
IgG1 MCPC-21 mouse PE-Cy7 BD, Heidelberg 
IgG2a G155-178 mouse FITC BD, Heidelberg 
IgG2a X39 mouse PE BD, Heidelberg 
IgG2b MCP-11 mouse PE BD, Heidelberg 
IgG2b MOPC-195 mouse APC Caltag, Buckingham. UK 
 
Unconjugated antibodies:  
Specificity Isotype Clone Source Manufacturer 
CD8 IgG2a UCHT-4 mouse Leinco 
CD80 IgG1 37711 mouse R&D Systems, Wiesbaden-
Nordenstadt 
CD86 IgG1 37301 mouse R&D Systems, Wiesbaden-
Nordenstadt 
CD209 IgG2b 120507 mouse R&D Systems, Wiesbaden-
Nordenstadt 
ICAM-1 IgG1 BBIG-I1 mouse R&D Systems, Wiesbaden-
Nordenstadt 
ICAM-2 IgG - goat R&D Systems, Wiesbaden-
Nordenstadt 
PD-L1 IgG1 MIH1 mouse eBioscience, Frankfurt 
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2.1.5. Chemical Reagents and Dyes 
Reagent Applied concentration Manufacturer 
7AAD 5µL / stain BD, Heidelberg 
AnnexinV- FITC 5µL / stain Caltag, Buckingham. UK 
Bafilomycin 100nM Sigma-Aldrich, Steinheim 
Blebbistatin 50µM Sigma-Aldrich, Steinheim 
Concanamycin A 0.1µg/mL Sigma-Aldrich, Steinheim 
eFluor 710 Streptavidin 30µL / stain eBioscience, Frankfurt 
Golgi-Stop (Monensin) 0.7µL / mL BD, Heidelberg 
Lck inhibitor II 100µM Calbiochem, Darmstadt 
PHA-L 1µg/mL Sigma-Aldrich, Steinheim 
PKH26 1.5µL / 400µL Sigma-Aldrich, Steinheim 
PKH67 1.5µL / 400µL Sigma-Aldrich, Steinheim 
APC Streptavidin 10µL / stain BD, Heidelberg 
Sulfo-NHS-LC-Biotin 5µL / mL Pierce, Rockford, USA 
 
2.1.6. Beads 
Name Manufacturer 
CD4+ T cell isolation Kit Miltenyi Biotech, Bergisch-Gladbach 
CD8+ T cell isolation Kit Miltenyi Biotech, Bergisch-Gladbach 
DN  T cell isolation Kit Miltenyi Biotech, Bergisch-Gladbach 
NK cell isolation Kit Miltenyi Biotech, Bergisch-Gladbach 
B cell isolation Kit Miltenyi Biotech, Bergisch-Gladbach 
Anti-PE MicroBeads Miltenyi Biotech, Bergisch-Gladbach 
Anti-CD4 Microbeads Miltenyi Biotech, Bergisch-Gladbach 
Anti-CD8 Microbeads Miltenyi Biotech, Bergisch-Gladbach 
Dynabeads® CD3/CD28 T Cell Expander Dynal, Invitrogen, 
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2.1.7. Cell culture flasks, tubes and plates  
Name Manufacturer 
Filter Cap Cell Culture Flask, 50mL Greiner, Frickenhausen 
Filter Cap Cell Culture Flask, 250mL Greiner, Frickenhausen 
Filter Cap Cell Culture Flask, 650mL Greiner, Frickenhausen 
Polystyrene Cell Culture Tubes, 16mL BD, Heidelberg 
96-well U- bottom plates BD, Heidelberg 
96-well flat bottom plates Corning, USA 
24-well plates Corning, USA 
24-well tissue transwell culture plate Corning, USA 
culture dishes Falcon/BD, Franklin Lakes (USA) 
15 mL centrifugation tubes Falcon/BD, Franklin Lakes (USA) 
50 mL centrifugation tubes Falcon/BD, Franklin Lakes (USA) 
FACS tubes unsterile Sarstedt, Nürnbrecht 
Cryogenic storage tubes Greiner, Frickenhausen 
1,5 mL cups Sarstedt, Nürnbrecht 
2 mL pipettes Corning, USA 
5 mL pipettes Corning, USA 
10 mL pipettes Corning, USA 
25 mL pipettes Corning, USA 
50 mL pipettes Corning, USA 
 
2.1.8. Cytokines 
Cytokines Manufacturer 
GM-CSF Bayer, Leverkusen 
IFN-γ PeproTech, Hamburg 
IL-1β Promokine, Heidelberg 
IL-4 Promokine, Heidelberg 
IL-6 Promokine, Heidelberg 
PGE2 Enzo Life Sciences, Lörrach 
TGF-β Promokine, Heidelberg 
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Cytokines Manufacturer 
TNF Promokine, Heidelberg 
 
2.1.9. Cell lines 
Cell line Properties Reference/Source 
Mel1300 HLA-A2+, Melan A+, gp100+ Mackensen A, Carcelain G 
et al., 1994 
 J Clin Invest 
Na8 HLA-A2+, TAA- Feder-Mengus C, Ghosh S 
et al., 2007,  
Br J Cancer 
Laz388 EBV transformed lymphoid B 
cell line 
Piper AA, Tattersall MH, 
Fox RM, 1980  
Biochim Biophys Acta 
T2 Hybrid cell line of T- and B-
LCL, HLA-A2+, TAP 
deficient 
Salter RD, Howell DN, 
Cresswell P, 1985 
Immunogenetics 
 
2.1.10. Software 
GraphPad Prism 5.02 (GraphPad, La Jolla, USA) was used for generation of graphs and 
calculation of statistics. FACS Data was acquired by a FACSCanto II using BD FACSDiva 
Software (BD, Heidelberg) for data acquisition. FlowJo software PC version 7.6 (Celeza, 
Olten, Switzerland) was used for analysis of FACS data. Data of confocal microscopy was 
processed by the programm ZEN Light Edition (Zeiss, Jena, Germany) 
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2.2. Methods 
2.2.1. Determination of cell numbers using trypan blue staining 
The cell number was determined in a solution of 0.4% of trypane blue (Gibco) diluted in 
distilled water. This life dead staining allows counting of living cells. Only dead cells with 
a damaged membrane-integrity absorb the blue dye. For calculating the cell number per 
mL, the following formula was used: 
 
 Number of living cells 
               x  dilution  x  10000 = cell number/mL 
Number of counted quadrants  
 
2.2.2. Cryoconservation of cells 
For cryoconservation the cell number was determined and washed once with PBS.  Cells 
were adjusted up to 100x106 per mL in freeze media. The cell suspension was transferred to 
a pre-cooled cryogenic storage tube and put into a 4°C cooled cryo freezing container 
(Nalgene Nunc, International Hereford, U.K.). The freezing container was stored at -80°C 
over night, and then the samples were put into liquid nitrogen for long time storage. 
 
2.2.3. Thawing of cells  
A defined amount of medium was added to deep-frozen cells by and by until cells were 
completely thawed. Cells were subsequently centrifuged and resuspended in fresh medium. 
 
2.2.4. Density gradient centrifugation 
The appropriate cells were taken from healthy donors by leukapheresis and diluted 1:1 with 
PBS. Pancoll was coated with this cell fraction and centrifuged (900g, 4°C, 20’). This 
density gradient centrifugation leads to a separation of a heavy fraction (erythrocytes), an 
interphase (mononuclear cells, MNC) and the supernatant containing thrombocytes. The 
interphase was harvested and washed twice with PBS (300g, 10’). Afterwards, the cell 
number was adjusted and MNC fraction was frozen or utilized for monocyte extraction.   
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2.2.5. Isolation of monocytes by countercurrent elutriation 
One part of MNC obtained from density gradient centrifugation was adopted for 
countercurrent elutriation. Therefore, MNC were centrifuged using J-6M/E Elutriator, 
Beckman Coulter, whereas cells were separated according to size and density. First the 
system was sterilized using H2O2, washed with PBS and the pump was calibrated with 
Hanks´ buffer. To prevent cells from damage, 6% of autologous plasma was added to 
Hanks´ buffer for elutriation. The separation of particular cell fractions is carried out by 
continuously rising flow rate and constant speed of the centrifuge. According to the 
separation, cells were collected in fractions and the final fraction III (monocytes) was 
centrifuged (1500rpm, 10’, 4°C) and resuspended in fresh media.  
 
2.2.6. Cultivation of cell lines 
Adherent cell lines: Tumor cell lines were cultured as monolayers in media containing 
FCS (B´) in 25cm2 tissue culture flasks at 37°C, 5% CO2. To detach the cells from the 
bottom of the flasks, adherent cells were incubated with trypsin-EDTA (Gibco/Invitrogen, 
Karlsruhe) and washed with PBS. Afterwards tumor cells were sub-cultured twice a week 
by diluting 1:10 in fresh medium.  
Suspension cell lines: In contrast, Laz and T2 were cultivated in B´ medium in 25cm2 
tissue culture flasks at 37°C, 5% CO2. B cells were harvested followed by washing with 
PBS and were sub-cultured twice a week by diluting 1:10 in fresh medium. 
 
2.2.7. Generation of DC from monocytes 
Monocytes obtained from elutriation were adjusted to 1x106 per mL B´ medium and were 
differentiated by addition of IL-4 (25U/mL), GM-CSF (800U/mL) and 5ng/mL TGF-β on 
day 1. On day 6, proinflammatory cytokines IL-1β (10ng/ml), IL-6 (1000U/ml), TNF 
(10ng/mL), and prostaglandine E2 (1µg/mL) as well as further IL-4 (12.5U/mL) and GM-
CSF (400U/mL) were added for another 48h to obtain mDC. 
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2.2.8. Antigen-pulsing of antigen-presenting cells 
mDC (or other kind of APC) were washed in serum free medium M´ and  adjusted to a 
densitiy of 3-5x106 cells/mL M´. 30µg/mL peptide and 10µg/mL β−2microglobulin (β-2m) 
(Scipac, Sittingbourne, UK) stabilizing the MHC-complexes was added to the cell 
suspension and was incubated at 37°C, 5% CO2. Tubes were shaken from time to time to 
avoid adhesion of DC at the plastic-tube. After 2h, APC were washed two times with serum 
supplemented medium to remove excessive peptide. 
 
2.2.9. Magnetic cell separation 
The magnetic cell sorting was carried out using diverse isolation kits by Miltenyi for the 
isolation of diverse immune cell populations as listed in the table above. MNC were labeled 
in a two-step-staining procedure. In the first step, Hapten-antibodies (monoclonal mouse 
anti-X antibody) which are diluted in MACS-buffer were used whereas in the second step 
anit-Hapten-antibodies (monoclonal AB beads anti-mouse-isotype) were added secondary. 
As far as applied beads only have a diameter of 50nm (Microbeads), the bead-labeled cell 
suspension has to pass special columns which are densely packed with iron-particles. 
Different column sizes are provided by the manufacturer depending on the number of cells 
and kind of isolation kit (MS-, LS-, LD-columns) (Miltenyi, Bergisch Gladbach). Columns 
were washed with MACS-buffer before usage. CD4+, CD8+, NK and B cells were isolated 
via a so-called negative selection meaning that cells of the unwanted phenotype were 
depleted via the labeling with the Microbeads. Thus, unwanted cells adhered via magnetic 
forces in the column, whereas cells of the wanted phenotype passed through and were 
collected afterwards. In contrast, the isolation of DN T cells consisted of a negative 
selection followed by two positive selection steps via binding of the TCRαβ. In unpurified 
DN cell cultures, both CD4+ and CD8+ T cells were depleted via Microbeads. Exact 
information about the particular antibodies against targets on unwanted cell populations for 
the negative selection is provided in the manufacturer’s protocol as well as amounts of used 
buffers, antibodies, and incubation times. Purity of isolated cell population was checked by 
flow cytometry. 
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2.2.10. Cultivation of T cells 
Generation of antigen-specific T cells 
CD8+ T lymphocytes were enriched by magnetic negative selection by Miltenyi separation 
system. Enriched T cell population showed a purity of more than 90%. Autologous, 
peptide-pulsed mDC served as stimulator cells. For antigen-specific expansion, 1x105 CD8+ 
cells/well were cultured with 2x104 peptide-pulsed mDC/well in 96-well-U-bottom-plates 
in 225µL/well T-cell stimulation medium which was exchanged every third or fourth day. 
Restimulation cycles were performed weekly under same conditions. Purity and antigen-
specificity of T-cell cultures were analyzed via flow cytometry. 
 
Generation of allo-specific CD4+, CD8+, and DN T-cell cultures 
Allogeneic T-cell stimulation was performed in a mixed lymphocyte reaction (MLR). 
Thereby, differences in MHC restriction between T cells and mDC mediate the stimulatory 
effect since T cells recognize non-self MHC molecules as target molecules. CD4+, CD8+ 
and DN T cells were separated out of MNC via magnetic cell separation with the Miltenyi 
system. T cells were stimulated with mDC from a completely MHC mismatch donor. 
7.5x104 CD4+, CD8+, or DN T cells/well were cultured with 2.5x104 mDC/well in 225µL 
T-cell stimulation medium/well in a 96-well U-bottom plate. Medium was exchanged every 
third or fourth day. Restimulation cycles were performed weekly under same conditions 
and purity was checked via flow cytometry.  
 
Cloning of CD8+ T cells 
To clone CD8+ T cells, 4x106 allogeneic MNC (irradiated with 30Gy) and 1x106 Laz388 
cells (irradiated with 60Gy) were disseminated per 96-well-plate. To assure close cell-to-
cell contact, cells were cultured in 150µL T-cell stimulation medium supplemented with 
0.225µL PHA-L (1mg/mL) in a V-bottom plate. Cells were stained with antibodies and 
subsequently sorted resulting in one to three cells per well under sterile conditions. Every 
fourth day, old medium was exchanged by fresh T-cell stimulation medium. Outgrowing 
clones were selected and disseminated in 96-well-U-bottom plates to be stimulated every 
second week with irradiated 6x105 allogeneic MNC/well and 1.5x105 Laz388/well in T-cell 
stimulation medium supplemented by PHA-L. Medium was exchanged every third or 
fourth day. Purity and specificity were checked by flow cytometry. 
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Polyclonal stimulation of CD4+, CD8+, and DN T-cells 
For polyclonal expansion of CD4+, CD8+ and DN T-cell populations, cells were cultured 
with T-cell expansion Dynabeads conjugated with anti-CD3 and anti-CD28 antibodies. 
Before stimulation, Dynabeads were washed in PBS supplemented with 0.1% BSA and 
subsequently added in a ratio of 1:1. Every third or fourth day, cells were transferred into 
fresh medium. Restimulation cycles were performed weekly. Therefore, beads were 
removed by a magnet, cells were counted and subsequently replaced in fresh medium in U-
bottom plates with new anti-CD3/CD28 Beads.  
 
2.2.11. Membrane labeling 
PKH is a lipophilic dye incorporating in the membrane bilayer without leaking or toxic side 
effects. 3-5x106 cells were washed with standard medium M´ in polystyrene culture tubes. 
Cells were resuspended in 200µL DilC and 200µL of staining solution (200µL DilC + 
1.5µL PKH dye) was added. Cells were incubated shaking at room temperature (RT) for 
20’. After 2h, human serum was added to stop the staining procedure and cells were 
washed two more times in T-cell medium.  
 
2.2.12. Trogocytosis experiments 
For trogocytosis experiments, antigen-presenting cells (mDC, T2 or Mel1300) were pulsed 
with 10µg/mL relevant or irrelevant peptide and 10µg/mL β-2 microglobulin at 37°C in 
serum-free standard medium. After 2h, target cells were stained with lipophilic membrane 
dye PKH67 as described before for 20’ at RT and washed three times with complete 
medium plus 10% human AB serum. Harvested T cell clones and target cells were placed 
in U-bottom well-plates (E:T ratio unless otherwise noted 3:1 = 7.5x105 T cells plus 
2.5x105 target cells in 200µL standard medium plus 10% human AB serum), incubated at 
37°C and harvested at indicated times. Harvested co-cultures were washed with PBS and 
resuspended before staining with monoclonal antibodies and analyzed by flow cytometry. 
Doublets were excluded in FACS analysis via FSC-W gating.   
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2.2.13. Transwell assay 
In a transwell-system, cells are separated via a membrane with pores to allow soluble 
factors of a certain size to pass trough. This system is dedicated to analyze whether a 
process is cell-to-cell contact dependent or can also be mediated by soluble factors. In this 
study, antigen-specific CD8+ T cells to be analyzed were added into the bottom chambers 
(3.0 x 105 per Well) of a 24-well tissue transwell culture plate. Into the insert well, PKH67 
labeled antigen-pulsed mDC (1.0 x 105 per insert) with or without antigen-specific PKH26 
labeled T cells (2.0 x 105 per insert) were placed as donor cells. Insert and bottom wells 
were separated by a membrane containing 5µm-pores which allow soluble factors and 
membrane vesicles but neither DC nor T cells to pass through. 
 
2.2.14. Experiments for inhibition of trogocytosis and apoptosis 
Preparation of DC lysates: mDC were antigen pulsed and membrane dye labeled as 
described before. Lysates were generated by repeated freeze-and-thaw cycles of a defined 
number of mDC. 
Blebbistatin (Inhibitor of Myosin IIa): T cells were pretreated with 50µM Blebbistatin for 
30 minutes at 37°C in standard medium. Afterwards, Blebbistatin was washed out and cells 
were subsequently used in the trogocytosis assay. 
Concanamycin A (CMA) / Bafilomycin (Inhibitors of vATPases): T cells or mDC were 
pretreated with 0.1µg/mL CMA or with 100nM Bafilomycin overnight in T-cell medium. 
vATPase inhibitor was washed out carefully before cells were put into trogocytosis assay as 
described before. 
Lck-inhibitor: T cells were pretreated with 100µM inhibitor for 1h at 37°C in standard 
medium. Lck-inhibitor was washed out subsequently before cells were used in the 
trogocytosis assay.  
Fixation of APC: PKH67 labeled, Mart-1 pulsed mDC were incubated for 30’ in 0.05% 
Glutaraldehyde-solution (Sigma-Aldrich) and were carefully washed with T-cell medium 
two times before they were used in the trogocytosis assay. 
Blocking antibodies: 10µg/mL high purified azide-free blocking antibodies were added to 
target cells 1h before co-culture in T-cell medium. Antibodies were not washed out but 
remained in the co-culture during trogocytosis assay. 
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2.2.15. Flow cytometry and cell sorting 
Flow cytometry is a method for detection of cells stained with fluorochrome labeled 
antibodies to perform phenotypic cell analysis but also cytokines, proliferation, or apoptosis 
can be detected by fluorescence in flow cytometry. This technique allows counting and 
examining cells by suspending them in a stream of fluid and passing them by laser beam. 
Three lasers were available in FASCanto II (BD, Heidelberg) to initiate fluorochromes for 
detecting the emission in 8 channels. This technique permits the detection of light scattering 
for each cell; the forward scatter provides information about the size of the cell whereas the 
side scatter informs about granularity. For the experiments FITC (Fluorescein 
isothiocyanate), PE (Phycoerythrin), PerCP (Perdinin chlorophyll protein complex), APC 
(Allophycocyanin), PE-Cy7 and APC-Cy7 were applied. This technique can also be used 
for fluorescence activated cell-sorting (FACS), thereby the wanted cells are sorted in terms 
of bound fluorochrome labeled antibodies identifying the wanted phenotype. Cell sorting of 
CD3+CD8+ clonal T cells for subsequent analysis after trogocytosis process was performed 
using a MoFlo cell sorter (Cytomation, Freiburg, Germany).  
 
2.2.16. FACS staining 
Direct antibody staining 
Surface antigens and intracellular proteins can be directly stained by fluoreochome-linked 
antibodies. Cells were harvested and transferred to FACS tubes (Sarstedt, Nürnbrecht) for 
surface staining. After washing twice with PBS, the indicated amount of monoclonal 
antibody was added to the cells and incubated at 4°C in the dark for 10 minutes. After a 
further washing step cells were resuspended in 200µL of PBS or fix solution. Analysis was 
carried out by FACSCanto II flow cytometer (BD, Heidelberg). The software Flowjo (Tree 
Star, Ashland, USA) was applied for evaluation of the data. Calculated mean fluorescence 
intensities (MFI) of antibody staining were corrected by subtraction of MFI of isotype 
background fluorescence. 
Annexin/7-AAD staining 
Early apoptotic cells expose phosphatidylserine at their surface which can be bound by 
AnnexinV. 7-Aminoactinomycin (7-AAD) intercalates in double-stranded DNA, thus it can 
be used for the identification of late apoptotic cells because it only stains cells with 
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disrupted plasma membrane. After surface antibody-staining, cells were incubated with 
5µL Annexin V FITC and 5µL 7-AAD in 150µL Annexin binding buffer at RT for 15’ in 
the dark followed by immediate FACS analysis.  
 
pMHC-tetramer staining 
pMHC-tetramer staining is a technique for the identification of specific TCR, thereby 
antigen-specific T cells can be identified via flow cytometry. For the detection of antigen-
specific T cells, cells were washed by PBS and were subsequently incubated with pMHC-
tetramers at RT for 30 minutes in the dark. Afterwards, surface antibodies were added 
without washing out the tretramers. After incubation time, cells were washed with PBS and 
analyzed by flow cytometry.  
 
2.2.17. Confocal immunefluorescence microscopy  
DC were labeled with membrane dye PKH67 as described above and T cells were labeled 
analogous with membrane dye PKH26. After co-culture for 2 hours at 37°C, cells were 
harvested, washed two times and incubated with α-PD-L1-Biotin or corresponding IgG-
Biotin antibody for 15’ at 4°C. Cells were washed two times before incubation with 
Streptavidin-eFluor710 nanocrystals for 20’ at 4°C followed by four washing steps with 
PBS. Cells were then fixed for 15’ at RT with 3% paraformaldehyde. Subsequently, cells 
were pipetted on adherent SuperFrost Plus microscope slides (Langenbrinck, 
Emmendingen, Germany). After settling and cell adherence, cells were washed once with 
PBS. Almost dried slides were mounted with ProLong Gold Antifade Reagent (Invitrogen, 
Darmstadt, Germany). Slides were analyzed utilizing a Zeiss laser scanning microscope 
(Zeiss LSM 700, Jena, Germany) with the respective ZEN software (Vers. 2009). Images 
were captured with a 63x oil objective (NA 1.4) and 12-bit sequential scans. A 5 times 
zoom was used for high resolution single cell images, this is within the reasonable range of 
Nyquist Theorem and therefore avoiding loss of resolution by undersampling. Pictures were 
additionally post-preocessed by linear unmixing. 
 
2.2.18. Transfection of mDC with GFP-RNA 
mDC were harvested on day 7 of differentiation and washed with RPMI, then washed with 
Optimem at RT and resuspended in 100μL Optimem. 5μg of GFP-RNA was put in a 
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cuvette (Peqlab, Erlangen) and 100μL of the cell suspension was added. The GFP-RNA 
was provided by Dr. Niels Schaft and Dr. Jan Dörrie, Dept. of Dermatology, University of 
Erlangen-Nuremberg. Cells were electroporated in a 4mm gap cuvette using a square wave 
pulse, at 500V for 1ms with a Biorad Gene Pulser. Immediately after transfection, cells 
were transferred to 10mL DC medium containing IL-4, GM-CSF, IL-1β, IL-6, TNF and 
PGE2. After 4h, cells were harvested and incubated for 24h before the use in the 
trogocytosis assay. 
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3. Results 
3.1. Characterization of T-cell clones specific for Mart-1 peptide and for 
gp100 peptide 
For following experiments analyzing trogocytosis, a human Mart-1-specific and a gp100-
specific CD8+ T-cell clone was used in trogocytosis experiments. The specificity of the T-
cell clones was regularly checked by tetramer-technology as shown in Figure 3. T-cell 
clones only with a purity of more than 85% antigen-specific T cells were used in 
experiments.  
 
Figure 3: Specificity of human T-cell clones. Mart-1- and gp100-specific T cell clones were stained by 
TCR-specific tetramers to ensure specific antigen-recognition. Dot plots are gated on vital singlet T cells. 
Shown is one representative of more than five independent experiments. 
 
3.2. Capture of cell components from mDC by T cells 
Trogocytosis is described as intercellular transfer of membrane fragments from presenting 
cell to lymphocyte (Joly and Hudrisier 2003). To investigate whether membrane 
components are transferred, acquisition of lipids and proteins was analyzed after antigen-
specific recognition using a Mart-1-specific human T-cell clone. After co-culture of Mart-
1-specific CD8+ T cells with Mart-1 peptide-pulsed mDC that were either labeled with 
lipophilic membrane dye PKH26 or with biotinylated proteins for detection by NHS-
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Streptavidin, lipid components (PKH26) and proteins (NHS-Streptavidin) were both 
transferred from mDC onto T cells in an antigen-specific manner (see Figure 4). 
 
 
Figure 4: Antigen-specific acquisition of both, lipids and proteins of the plasma membrane from mDC 
by T cells.  Mart-1-specific T cells were co-cultured for 2h with Mart-1 peptide-pulsed, PKH26-labeled or 
biotinylated mDC. Uptake of either lipid- or protein-labeled membrane fragments was analyzed on T cells by 
flow cytometry via detection of either PKH26 or NHS-Streptavidin (black solid line). Negative controls are 
shown as filled histograms. Histograms are gated on CD8+ lymphocytes. Shown is one representative of three 
independent experiments. 
 
 
Next, it was analyzed which surface molecules are transferred from mDC onto antigen-
specific CD8+ T cells. Antigens that are known to be highly expressed on mDC such as 
CD209, PD-L1, PD-L2, CD80, CD83, and CD86 were analyzed on monocyte-derived 
mDC by flow cytometry (see Figure 5A). Of interest, after co-culture of Mart-1-pulsed 
mDC with Mart-1-specific T cells, PD-L1, CD209, and CD83, but not CD80, CD86, and 
PD-L2 were transferred onto T cells (see Figure 5B). As control, T cells were analyzed for 
those molecules before co-culture. Of note, the antigen-specific T-cell clone showed no 
CD83, CD209, PD-L1, and PD-L2 expression but a low constitutive expression of CD80 
and CD86 was documented.  
 
PKH26 NHS-Streptavidin
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Figure 5: Transfer of DC-specific surface molecules from mDC onto antigen-specific T cells. (A) 
Expression of surface molecules on mDC. mDC were analyzed by flow cytometry for expression of CD80, 
CD83, CD86, PD-L1, PD-L2, and CD209 (black solid line). Isotype controls are shown as filled histograms. 
(B) Mart-1specific CD8+ T-cell clone was screened for uptake of listed molecules after co-culture with Mart-
1-pulsed mDC. Transfer was analyzed after 2h of co-culture (black solid line) compared to constitutive 
surface expression on T cells without contact to mDC (filled histograms). Histograms are gated on CD8+ 
lymphocytes. Shown is one representative of three (PD-L1, CD209, CD83) or two (PD-L2, CD80, CD86) 
independent experiments. 
 
 
Next, the acquisition of green fluorescent protein (GFP) was analyzed as a model protein 
for cytosolic molecules. mDC were transfected with GFP-encoding RNA, which was 
transcribed and translated into protein in the cytosol. Of interest, GFP was also transferred 
from mDC onto CD8+ T cells suggesting that not only surface molecules but also cytosolic 
components can be acquired by T cells after antigen-specific recognition (see Figure 6). A 
control vector (mock) served as negative control.  
Together, lipids, and proteins of plasma membrane, surface molecules as PD-L1 and 
CD209 as well as cytosolic components are acquired from human mDC by T cells in an 
antigen-dependent manner. 
 
Figure 6: Antigen-specific acquisition of cytosolic GFP from mDC by T cells. mDC were transfected with 
RNA encoding GFP or with a control vector (mock). Transfer onto CD8+ T cells was analyzed after 2h of co-
culture (black solid line). Negative controls are shown as filled histograms. Histograms are gated on CD8+ 
lymphocytes.  Shown is one of four independent experiments. 
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3.3. Acquisition of membrane fragments and surface molecules by different T-
cell subsets 
Besides CD8+ T cells, other subpopulations of T cells as CD4+ and DN T cells may also be 
able to acquire membrane fragments and surface molecules such as CD209 via 
trogocytosis. To answer this question, purified CD4+, CD8+, and DN T-cell subpopulations 
were expanded in vitro by repetitive stimulation with allogeneic mDC, co-cultured with 
PKH26-labeled allogeneic mDC and were then analyzed by flow cytometry. As shown in 
Figure 7, T-cell subpopulations had a similar capacity to take up membrane patches and 
surface molecules from APC.  
 
 
 
 
Figure 7: Transfer of membrane fragments and CD209 from DC onto alloreactive T-cell 
subpopulations.  Alloreactive CD4+, CD8+, or DN T-cell lines were co-cultured with PKH26-labeled mDC. 
T cells were analyzed for transferred membrane fragments and CD209 from mDC via flow cytometry after 2h 
PKH26 CD209
CD4+ T cells
CD8+ T cells
DN T cells
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of co-culture (black solid line). Negative or isotype controls are shown as filled histograms. Histograms are 
gated on CD3+CD4+ lymphocytes (panel 1), CD3+CD8+ lymphocytes (panel 2), or TCRαβ+ CD4-CD8- DN T 
cells (panel 3). Shown is one of three representative experiments with similar results. 
 
 
3.4. Antigen-specificity of the trogocytosis process 
Trogocytosis has been described as an antigen-dependent process. Therefore the next 
question was whether membrane bound PD-L1 and CD209 on mDC could be also acquired 
by human CD8+ T cells in an antigen-independent manner. Mart-1-specific CD8+ T cells 
were co-cultured with PKH67-labeled mDC which were either pulsed with the cognate 
Mart-1 or irrelevant gp100-peptide. As shown in Figure 8A, T cells acquired high amounts 
of membrane patches, PD-L1, and CD209 after antigen-recognition but neither PD-L1 nor 
CD209 and just low amounts of membrane fragments after co-culture of T cells with 
control peptide pulsed DC.  
Next, confocal microscopy was performed to visualize the uptake of membrane patches and 
PD-L1 from APC. PD-L1 expression was detected on mDC but not on T cells by secondary 
nanocrystal staining in far red (data not shown). After exposure of Mart-1-specific T cells 
with peptide-pulsed DC, antigen-specific uptake of PD-L1 and membrane fragments by 
CD8+ T cells was documented (see Figure 8B). Of importance, PD-L1 and membrane 
patches did not co-localize and were found widespread over the T cells. Activation after 
antigen-recognition was documented by the increase of activation markers CD25 and 
CD137 as shown in Figure 9. 
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Figure 8: Transfer of membrane fragments, PD-L1 and CD209 from APC on T cells is antigen-specific. 
(A) Mart-1-specific CD8+ T cells were co-incubated with PKH67-labeled mDC that were pulsed either with 
Mart-1 peptide or an irrelevant gp100 control peptide. Acquisition of PKH67+ membrane fragments, PD-L1, 
and CD209 was measured on Mart-1 specific T cells after 2h of co-culture with DC+Mart-1 (upper panel) or 
with DC+gp100 control peptide (lower panel) by flow cytometry (black solid line). Dashed line in lower 
panel shows T cells before co-culture as negative control. Unstained or isotype controls are presented as filled 
histograms. Histograms are gated on CD8+PKH67low lymphocytes. Shown is one representative of five 
independent experiments. Filled histograms represent negative control for membrane stain and isotype control 
for antibody-stain. (B) Visualization of transferred membrane fragments and PD-L1 on T cells by confocal 
microscopy. mDC were pulsed with specific Mart-1 or control peptide gp100 followed by PKH67-labeling. 
Mart-1-specific CD8+ T cells were stained with PKH26. After 2h of co-culture with or without antigen-
recognition, cells were incubated with anti-PD-L1-Biotin followed by secondary Streptavidin-eFluor staining. 
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mDC served as positive and T cells as negative control (not shown). In the upper panel, one representative 
zoomed T cell is shown after antigen-specific trogocytosis. In the lower panel, antigen-unspecific co-culture is 
shown as control. In the fluorescence overlay (merge), PKH26-labeled T cells are shown in red, PKH67 is 
shown in green and PD-L1 in blue. 
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Figure 9: Upregulation of activation markers on T cells after antigen-specific or –non-specific 
recognition. Mart-1-specific CD8+ T cells were co-incubated with PKH67-labeled mDC which were pulsed 
either with Mart-1 peptide or with control gp100 peptide. After 22h, expression of activation markers CD25 
and CD137 was measured on T cells. Dot plots are gated on CD8+PKH67low lymphocytes. Shown is one 
representative of three independent experiments. 
 
 
To investigate whether T cells can also perform trogocytosis from tumor cells in an 
antigen-specific manner, the HLA-A2+, tumor associated antigen negative (TAA-) 
melanoma cell line Na8 either or not pulsed with Mart-1 peptide and labeled with PKH67 
was co-cultured with Mart-1-specific T cells. T cells interacting with antigen-pulsed Na8 
cells acquired more membrane fragments than from the negative control without antigen 
(see Figure 10A). Moreover, activation markers such as CD25 and CD137 were only up-
regulated after antigen-specific interaction (see Figure 10B). This shows that also in the 
interaction with target cells as tumor cells, trogocytosis is triggered by antigen-recognition. 
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Figure 10: Trogocytosis from melanoma cell line is triggered by antigen-recognition.  Na8 melanoma 
cells either (+Mart-1) or not (w/o peptide) pulsed with antigen Mart-1 peptide and labeled with PKH67 were 
co-cultured with Mart-1-specific T cells. (A) After 2h, uptake of membrane fragments was analyzed by flow 
cytometry (black solid line). Negative controls are presented as filled histograms. (B) After 22h, expression of 
activation markers CD25 and CD137 was measured on T cells. Histograms and dot plots are gated on 
CD8+PKH67low lymphocytes. Shown is one representative of three independent experiments 
 
 
 
 
3.5. Role of antigen-presenting cells for the transfer of membrane fragments 
and surface molecules onto T cells 
3.5.1 Capacity of different APC sources in the trogocytosis process 
Next, the potential of CD8+ T cells to acquire membrane patches from different APC 
sources via trogocytosis was analyzed. Purified peptide-pulsed and PKH67-labeled 
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monocytes, iDC, mDC, NK cells, or B cells were co-culture with Mart-1-specific T cells. 
As shown in Figure 11, T cells were able to acquire only low amounts of membrane 
fragments from monocytes, NK cells, and B cells. In contrast, DC are the most potent 
donor cells with the capacity of transferring high amounts of membrane fragments onto 
CD8+ T cells. 
 
 
Figure 11: Transfer of membrane patches from different different APC sources onto T cells.  Purified 
monocytes, NK cells, B cells, iDC and mDC were pulsed with Mart-1 peptide and labeled with PKH67. Mart-
1-specific T cells were co-cultured with the different APC for 2h and analyzed for acquisition of membrane 
fragments (black solid line). Negative controls are shown as filled histograms. Histograms are gated on CD8+ 
PKH67low lymphocytes. Shown is one representative of three independent experiments with similar results. 
 
 
To compare the transfer of surface molecules and membrane fragments from iDC and mDC 
onto CD8+ T cells in more detail, expression of surface molecules such as CD80, CD86, 
PD-L1, and CD209 was analyzed. FACS analysis showed that mDC express higher levels 
of PD-L1, CD80, and CD86 (see Figure 12), whereas CD209 was expressed on iDC and 
mDC at similar levels. 
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Figure 12: Expression of CD80, CD86, PD-L1 and CD209 on iDC versus mDC. mDC and iDC were 
analyzed by flow cytomtery for expression of co-stimulatory, co-inhibitory and DC-specific molecules (black 
solid line). Isotype controls are presented as filled histograms. Shown is one representative of three 
independent experiments. 
 
 
Since iDC and mDC have comparable expression levels of PD-L1 and CD209, these 
antigens were used for further studies. As shown in Figure 13, CD8+ T cells acquired higher 
amounts of membrane fragments on their cell surface, but also significantly higher levels of 
surface PD-L1 and CD209 molecules from mDC compared to iDC. 
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Figure 13: mDC are more efficient in transferring both, membrane patches and surface molecules onto 
T cells. iDC and mDC were pulsed with Mart-1 peptide and labeled with PKH67. After 2h of co-culture, 
Mart-1-specific CD8+ T cells were analyzed for acquisition of PKH67, PD-L1, and CD209 by flow cytometry 
(black solid line). Negative or isotype controls are shown as filled histograms. Histograms are gated on 
CD8+PKH67low lymphocytes. Shown is one representative of three independent experiments. 
 
3.5.2. Transfer of membrane fragments and molecules from melanoma cells 
Next, it was determined whether tumor antigen-specific CD8+ T cells are also capable of 
acquiring surface molecules from tumor cells upon antigen-specific recognition. The co-
inhibitory molecule PD-L1 is up-regulated on many melanoma cell lines after IFN-γ 
exposition, whereas the surface antigen melanoma chondroitin sulphate proteoglycan 
(MCSP) is known to be constitutively expressed (Dong, Strome et al. 2002). The HLA-A2+ 
Mart-1+ melanoma cell line Mel1300 was analyzed for PD-L1 and MCSP before and after 
IFN-γ exposure and revealed a high MCSP expression that was not modulated by IFN-γ 
(see Figure 14). As expected, PD-L1 was not constitutively expressed on Mel1300 but was 
induced up to 90% PD-L1+ melanoma cells after pretreatment with IFN-γ. 
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Figure 14: Expression of PD-L1 and MCSP on melanoma cell line Mel1300 before and after IFN-γ 
treatment. PD-L1 and MCSP expression was analyzed on Mel1300 before (upper panel) and after 48h IFN-γ 
(lower panel) exposure by flow cytometry and is shown as black solid line in histograms. Isotype controls are 
presented as filled histograms. Shown is one representative of three independent experiments. 
 
 
After co-culture with IFN-γ treated Mel1300 cells T cells acquired both, PD-L1 and MCSP, 
besides membrane fragments whereas no PD-L1 could be detected on T cells after co-
culture with IFN-γ−untreated Mel1300 melanoma cells (see Figure 15). Although PD-L1 
can be acquired by T cells after antigen-recognition from PD-L1+ tumor cells, less 
molecules and membrane fragments are transferred from melanoma cells than from mDC. 
These data demonstrate that PD-L1 is not exclusively acquired from mDC but also from 
PD-L1 expressing melanoma cells. 
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Figure 15: Acquisition of PD-L1 and MCSP from the melanoma cell line Mel1300 by CD8+ T cells. 
PKH67 labeled, IFN-γ pre- or untreated Mel1300 melanoma cells were co-cultured with Mart-1 specific CD8+ 
T cells. Acquisition of membrane fragments, PD-L1 and MCSP was analyzed after 2h by flow cytometry 
(black solid line). Negative or isotype controls are presented as filled histogram. Histograms are gated on 
CD8+PKH67low lymphocytes. Shown is one representative of three independent experiments.  
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3.6. Characterization of the trogocytosis process from APC 
3.6.1. PD-L1 is not up-regulated on antigen-specific T cells 
PD-L1 is described to be endogenously expressed by T cells after stimulation (Keir, Butte 
et al. 2008). To verify that PD-L1 is not up-regulated on T cells after stimulation, Mart-1-
pulsed, PKH67-labeled, PD-L1- T2 cells were used as stimulator cells for Mart-1-specific T 
cells (see Figure 16A). As shown in Figure 16B, the uptake of membrane fragments but not 
PD-L1 was detected on T cells. The transfer of PKH67 and PD-L1 from mDC onto T cells 
served as positive control. These data suggest that PD-L1 is rapidly acquired from PD-L1+ 
mDC upon antigen-specific stimulation during antigen-specific interaction with mDC but 
not endogenously expressed on T cells within 2 hours.  
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Figure 16: PD-L1 acquisition by T cells is independent on endogenous PD-L1 expression. T2 cells and 
mDC were pulsed with Mart-1 peptide, labeled with PKH67 and co-cultured for 2h with Mart-1-specific 
CD8+ T cells. (A) Histograms show expression of PD-L1 on T2 cells and mDC (black solid line). (B) 
Histograms present the transfer of PKH67 and PD-L1 onto T cells gated on CD8+PKH67low lymphocytes. 
Filled histograms represent negative control for membrane staining and isotype control for antibody-staining. 
Shown is one representative of three independent experiments. 
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3.6.2. Acquisition of membrane fragments and surface molecules is dependent 
on the activation status of T cells 
Next, the influence of the activation status of T cells on trogocytosis was analyzed. 
Antigen-specific as well as non-specific transfer was performed with CD8+ T cells that 
were stimulated overnight with anti-CD3/CD28 beads or PHA-L. Prestimulation resulted  
in a slightly increased acquisition of membrane fragments and surface molecules on 
antigen-specific T cells in both cases (see Figure 17A). CD25 expression was up-regulated 
on the Mart-1-specific T-cell clone upon prestimulation with anti-CD3/CD28 beads and 
PHA-L. In contrast, polyclonal, unstimulated T cells did not acquire any surface molecules 
and membrane patches but could be triggered to acquire small amounts of membrane 
fragments and CD209 upon prestimulation with anti-CD3/CD28 beads as well as PHA-L 
(see Figure 17B). Polyclonal T cells revealed a mixed phenotype of activated and not 
activated cells (data not shown). After incubation in medium overnight, CD25 was down-
regulated. In contrast, CD25 was highly expressed on polyclonal T cells after 
prestimulation with either anti-CD3/CD28 beads or PHA-L. Together, prestimulated T cells 
can generally acquire more membrane fragments and surface molecules than unstimulated 
T cells. 
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Figure 17: Transfer of membrane fragments and surface molecules of APC onto T cells is dependent on 
the activation status of T cells. (A) Antigen-specific CD8+ or (B) polyclonal CD8+ T cells were either 
stimulated overnight with anti-CD3/CD28 beads or PHA-L, or cultured in medium. Beads were then removed 
and PHA-L was washed out. T cells were subsequently co-cultured with Mart-1 peptide-pulsed, PKH67-
labeled mDC. After 2h, acquisition of membrane fragments and CD209 (black solid line) as well as the 
expression of activation marker CD25 was measured by flow cytometry. Negative or isotype controls are 
presented as filled histograms. Histograms are gated on CD8+PKH67low lymphocytes. Shown is one 
representative of three independent experiments. 
 
 
3.6.3. The amount of acquired molecules on T cells is dependent on the DC to 
T cell ratio 
To determine whether the amount of acquired molecules is higher if more APC are targeted 
by antigen-specific T cells, T cells were co-cultured with mDC at different ratios and 
analyzed for uptake of membrane fragments and PD-L1. An increase in acquired membrane 
fragments and PD-L1 was observed up to a T cell:DC ratio of 1:1 (see Figure 18). At a ratio 
of 3:1, a three-fold acquisition of membrane fragments and a two-fold transfer of PD-L1 
RESULTS 
 
 
    58
was documented compared to a 10:1 ratio. Saturation was documented at a T cell:DC ratio 
of 1:3. These data demonstrate a limited capacity in the transfer of cell components.  
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Figure 18: Influence of T cell to mDC ratio on the efficiency of uptake of membrane fragments and PD-
L1. mDC were pulsed with Mart-1 peptide, labeled with PKH67 and co-cultured with Mart-1-specific T cells 
at different T cell:DC ratios. Data were measured by flow cytometry. The x-fold increase of the MFI of 
unstimulated T cells of four independent experiments (+ SD) is shown for PKH67 and PD-L1 on 
CD8+PKH67low T cells. 
 
 
3.7. Kinetics of the transfer process 
To assess the dynamics of the transfer of membrane fragments, PD-L1 and CD209, the 
kinetics of trogocytosis were documented at different times. As shown in Figure 19, 
transfer of PD-L1, CD209, and membrane patches from mDC onto T cells was evident 
already at 30’ after co-culture. The acquisition of all three components peaked at 1.5h to 2h 
and rapidly decreased after 3h to 4h reaching a plateau for about 20h. Between 48h and 72h 
of co-culture, PD-L1, CD209 and membrane patches completely disappeared from the T-
cell surface. Of interest, the acquisition of membrane fragments, PD-L1, and CD209 
revealed the same kinetics indicating a similar mechanism of capture. 
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Figure 19: Kinetics of acquisition of membrane fragments, PD-L1, and CD209. Mart-1-specific T cells 
were co-cultured with Mart-1 peptide-pulsed, PKH67-labeled mDC. Acquisition of membrane patches, PD-
L1 and CD209 was analyzed by flow cytometry at indicated times and is displayed as MFI of PKH67 ●, PD-
L1: ▲, CD209: ■. Shown is one representative experiment. Kinetics were tracked three times for the 
acquisition of membrane fragments and two times for the acquisition of PD-L1 and CD209. 
 
 
3.8. Mechanism of the transfer process 
3.8.1. The transfer process from APC onto T cells requires cell-to-cell contact  
Trogocytosis is defined as cell-to-cell contact dependent mechanism. To assure that both, 
PD-L1 and CD209 are not transferred via membrane vesicles but in a cell-to-cell contact 
dependent manner, peptide-pulsed DC were placed in the presence (1) or absence (2) of 
PKH26-labeled antigen-specific T cells in the insert well separated from T cells in the 
bottom well. In both settings, no transfer of PD-L1, CD209, and membrane fragments 
could be documented as shown in Figure 20 (PD-L1: 6.0% + 3.8% (1) and 9.1% + 1.0% (2) 
of MFI of maximal antigen-specific uptake compared to 2.5% + 2.5% background MFI; 
p<0.001; CD209: 11% + 15.7% (1) and 4.1% + 0.8% (2) of MFI of maximal antigen-
specific uptake compared to 5.1% + 4.7% background MFI; membrane fragments: 5.4% + 
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1.5% (1) and 7.5% + 0.9% (2) of MFI of maximal antigen-specific uptake compared to 
1.0% + 0.4 % background MFI; p<0.001). These experiments strongly demonstrate that 
trogocytosis of PD-L1 and CD209 is dependent on cell-to-cell contact.  
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Figure 20: Acquisition of PD-L1 and CD209 by antigen-specific T cells is mediated by a cell-to-cell 
contact dependent mechanism. (A) Mart-1 peptide-pulsed, PKH67-labeled mDC and PKH26-labeled, Mart-
1-specific T cells were set into transwell insert separated by a membrane with 5µm pores from bottom well. 
Mart-1-specific CD8+ T cells set in bottom well were analyzed for acquisition of membrane fragments, PD-
L1, and CD209 after 2h by flow cytometry (black solid line). Negative or isotype controls are presented as 
filled histograms. Histograms are gated on CD8+PKH67lowPKH26- lymphocytes. (B) Mart-1-pulsed, PKH67-
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labeled mDC were set into insert well with or without PKH26-stained T cells separated from Mart-1-specific 
CD8+ T cells in bottom well. Data were analyzed by flow cytometry. In the bar graphs, MFI of the maximum 
transfer was set to 100%. Inhibited transfer is shown as percentage of maximum uptake of membrane 
fragments and PD-L1 of three independent experiments + SD (*** p<0.001, ** p<0.01 paired t test).  
 
 
3.8.2. Transfer from PD-L1 and CD209 is not mediated by soluble proteins of 
lysed mature dendritic cells 
Next, it was analyzed whether T cells capture membrane fragments and surface molecules 
out of cell lysates after antigen-specific killing of APC. When Mart-1 peptide-pulsed, 
PKH67-labeled mDC were lysed via repeated freeze-and-thaw cycles, no transfer of PD-L1 
and CD209 but low amounts of membrane fragments was documented as shown in Figure 
21 (PD-L1: 8.2% + 3.1% MFI of maximal transfer compared to 5.3% + 2.4% background 
MFI, p<0.01; CD209: 21.4% + 5.5% MFI of maximal transfer compared to 5.7% + 9.9% 
background MFI, p<0.01; membrane fragments: 26.4% + 28.4% MFI of maximal transfer 
compared to 5.9% + 2.0 % background MFI, not significant). These data confirm that 
surface molecules are not captured after mDC lysis as consequence of the cytotoxic activity 
of T cells but upon close interaction with mDC. 
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Figure 21: No impact of cell lysis of mDC on acquisition of surface molecules by T cells. Mart-1-pulsed, 
PKH67-labeled mDC were lysed by freeze-and-thaw cycles and incubated with Mart-1-specific CD8+ T cells 
for 2h. As control, Mart-1-specific CD8+ T cells were co-cultured with Mart-1 peptide-pulsed, PKH67-labeled 
mDC. Negative or isotype controls are presented as filled histograms. (A) Histograms are gated on 
CD8+PKH67low lymphocytes. Shown is one representative of three independent experiments with similar 
results. (B) In bar graphs, MFI of antigen-specific transfer was set to 100% as maximum. Inhibited transfer 
and no transfer are shown as percentage of maximum uptake of membrane fragments and PD-L1 of three 
independent experiments + SD (transfer PKH: not significant (ns) paired t test; PD-L1 ** p<0.01 paired t 
test). 
 
3.8.3. Bystander T cells are not triggered to trogocytosis by neighboring T 
cells 
Unspecific bystander T cells were tested for increased antigen-unspecific acquisition of 
membrane fragments after co-culture with Mart-1-specific T cells and Mart-1-pulsed, 
PKH26-labeled mDC. Of interest, bystander T cells were not triggered indirectly by 
cytokines or interacting cells to acquire more membrane fragments than those T cells that 
are non-reactive to the exposed antigen (see Figure 22). These data clearly demonstrate that 
the trogocytosis process is specific and can not be transferred to unspecific bystander T 
cells. 
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Figure 22: Trogocytosis is a direct process between antigen-specific T cells and APC and not 
transferred onto non-specific bystander T cells.  Mart-1 peptide-pulsed and PKH67-labeled mDC were co-
cultured for 2h with CD8+ T cells that are either specific for the cognate Mart-1 peptide (Antigen-specific T 
cells in co-culture with only one T-cell population) or for the control gp100 peptide  (Antigen-unspecific T 
cells in co-culture with only one T-cell population). On the right panel, Mart-1-pulsed, PKH67-labeled mDC 
were co-cultured with both Mart-1-specific and gp100-specific T cells as bystander T cells. Co-cultures were 
analyzed for the uptake of membrane patches on antigen-specific or –unspecific T cells by flow cytometry 
(black solid line). Negative controls are presented as filled histograms. Shown is one representative of four 
independent experiments with similar results. 
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3.9. Inhibition of trogocytosis 
In order to explore the mechanism by which T cells acquire membrane fragments, several 
approaches were tested for their capacity to block trogocytosis.  
 
3.9.1. Impairment of trogocytosis by fixation of DC 
Next, the requirement for active involvement of mDC in the trogocytosis process was 
analyzed. To address this question, antigen-pulsed, PKH67-labeled mDC were fixed with 
0.05% glutaraldehyde and co-cultured with specific CD8+ T cells. As shown in Figure 23, 
fixation of mDC resulted in a strong inhibition of the transfer of membrane fragments, PD-
L1, and CD209.  
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Figure 23: Impairment of trogocytosis by fixation of APC. Before co-culture, mDC were pulsed with 
Mart-1 peptide, labeled with PKH67 and fixed with 0.05% glutaraldehyde. After 2h, transfer of PKH67, PD-
L1, and CD209 from fixed mDC onto T cells was analyzed by flow cytometry. Unfixed mDC served as 
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positive control. Negative or isotype controls are presented as filled histograms. Shown is one representative 
of three independent experiments with similar results. 
 
Of importance, TCR-pMHC interactions between T cells and glutaraldehyde-fixed mDC 
must still be functional as demonstrated by the up-regulation of CD25 and CD137 on T 
cells after co-culture with fixed mDC (see Figure 24). These data clearly indicate that the 
acquisition is not caused by disruption of molecules out of the membrane of DC but 
depends on direct interaction of vital mDC with T cells.   
 
 
Figure 24: Activation of CD8+ T cells after stimulation with fixed mDC. Mart-1-specific T cells were co-
cultured with fixed or unfixed Mart-1-pulsed, PKH67-labeled mDC. After 22h, expression of activation 
markers CD25 and CD137 was analyzed by flow cytometry compared to unstimulated T cells. Histograms are 
gated on CD8+PKH67low lymphocytes. Shown is one representative of three independent experiments. 
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3.9.2. Impact of surface molecules on T cells and DC for trogocytosis 
Next, surface molecules such as adhesion molecules and co-stimulatory and inhibitory 
molecules were blocked to analyze whether the interaction of these molecules plays an 
important role in triggering trogocytosis. To address this question, the co-receptor CD8, 
adhesion molecules ICAM-1 and ICAM-2 on antigen-specific CD8+ T cells as well as co-
stimulatory/-inhibitory molecules CD80 and CD86, PD-L1, and adhesion molecule CD209 
on mDC were blocked by specific blocking antibodies. After co-culture, antigen-specific T 
cells were analyzed by flow cytometry. With the exception of CD8 (see Figure 25), 
blocking of ICAM-1 and ICAM-2 on T cells as well as blocking of PD-L1, CD209, CD80, 
and CD86 had no influence on the uptake of membrane fragments and surface molecules by 
T cells (Figure 26). 
 
 
Figure 25: Blocking the CD8 co-receptor impairs trogocytosis. For blocking the CD8 co-receptor, CD8+ T 
cells were incubated for 30’ with blocking anti-CD8 antibody or with isotype control. CD8+ T cells were then 
analyzed for acquisition of membrane fragments and CD209 after co-culture. Specific transfer is presented as 
black solid line, transfer with CD8 blockade as black dashed line, and negative or isotype controls are 
presented as filled histograms. Shown is one representative of three independent experiments. 
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Figure 26: Impact of blocking surface molecules on trogocytosis of membrane patches and PD-L1. 
Antigen-specific CD8+ T cells were pre-treated for 30’ at 4°C with blocking anti-ICAM-1, anti−ICAM-2, or 
no antibody and were subsequently co-cultured with Mart-1-pulsed, PKH67-labeled mDC for 2h (left panel). 
Mart-1-pulsed, PKH67-labeled mDC were pretreated for 30min at 4°C with either anti-PD-L1, anti-CD80, 
anti-CD86, anti-CD209, or no blocking antibody and subsequently co-cultured with Mart-1-specific CD8+ T 
cells for 2h (right panel). CD8+ T cells were analyzed for acquisition of membrane fragments and PD-L1 
(black solid line). Negative or isotype controls are presented as filled histograms. Histograms are gated on 
CD8+PKH67low lymphocytes. Shown is one representative of two independent experiments.  
 
 
3.9.3. Trogocytosis is not impaired by inhibitors of stability of the 
immunological synapse 
Myosin IIA is described to play a role in the stability of the immunological synapse as well 
as in TCR signaling (Limouze, Straight et al. 2004; Ilani, Vasiliver-Shamis et al. 2009). 
The formation of cSMAC and pSMAC which can be impaired by pretreatment of T cells 
with blebbisatin may be important for induction of trogocytosis in human T cells. To 
address this point, Mart-1-specific T cells were treated with 50µM blebbistatin and co-
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cultured with Mart-1-pulsed, PKH67-labeled mDC. Despite the blebbistatin treatment, 
trogocytosis was not impaired as shown in Figure 27A, thus organization of the 
immunological synapse is neither important for the transfer nor for the up-regulation of 
activation markers CD25 and CD137 after triggered TCR signaling (see Figure 27B). 
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Figure 27: Trogocytosis by T cells is not impaired by prevention of cSMAC and pSMAC formation. T 
cells were pretreated with blebbistatin, a myosin IIA inhibitor. (A) After 2h of co-culture with antigen-pulsed, 
PKH67-labeled mDC, blebbistatin-treated CD8+ T cells were analyzed for acquisition of membrane patches 
and PD-L1 compared to control T cells by flow cytometry (black solid line). Negative or isotype controls are 
presented as filled histograms. (B) The activation of T cells was measured by CD25 and CD137 expression 
after 22h of co-culture. Histograms and dot plots are gated on CD8+PKH67low lymphocytes. Shown is one 
representative of three independent experiments with similar results.  
 
 
3.9.4. TCR signaling has no influence on trogocytosis by T cells  
Lck signaling is described to augment the transfer of MICA from target cells onto NK cells 
(McCann, Eissmann et al. 2007). Hence, CD8+ T cells were pre-treated with an inhibitor of 
Lck, a src family kinase playing a pivotal role in TCR signaling, and analyzed for 
trogocytosis onto antigen-specific CD8+ T cells. In contrast to the transfer of MICA, no 
decrease in acquisition of membrane patches, PD-L1, and CD209 was observed (see Figure 
28).  
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Figure 28: Trogocytosis is not impaired by inhibition of Lck. T cells were pre-incubated with 100µM Lck 
inhibitor or an appropriate amount of DMSO. Lck inhibitor or DMSO was washed out before trogocytosis 
assay with antigen-pulsed, PKH67-labeled mDC. After 2h, CD8+ T cells were analyzed for the uptake of 
membrane fragments, PD-L1 and CD209 (black solid line). Antigen-specific transfer is shown as dashed line. 
Negative or isotype controls are presented as filled histograms. Histograms are gated on CD8+PKH67low 
lymphocytes. Shown is one representative of three independent experiments.  
 
3.9.5. vATPases in T cells play an important role in trogocytosis  
vATPases were described to play a role in membrane trafficking as well as endo- and 
exocytosis (Marshansky and Futai 2008). It was determined whether concanamycin A 
(CMA), a specific inhibitor of vATPases, is able to abrogate antigen-specific trogocytosis 
(Huss and Wieczorek 2009). To address this question, T cells, DC, or both cell populations 
were exposed to CMA before co-culture and CD8+ T cells were analyzed for trogocytosis. 
Inhibition of vATPases in mDC resulted in a slightly reduced acquisition of membrane 
patches, PD-L1 and CD209 by T cells. Moreover, CMA-treatment of T cells strongly 
inhibited the transfer of PD-L1 (13.1% + 3.8% MFI of maximal transfer compared to 4.5% 
+ 1.2 % background MFI, p<0.001) and CD209 (40.0% + 30.5% MFI of maximal transfer 
compared to 29.0% + 19.9 % background MFI; ns) as well as the transfer of membrane 
fragments (28.8% + 8.0% MFI of maximal transfer compared to 6.3% + 3.3 % background 
MFI; p<0.001) (see Figure 29). Furthermore, combined exposure of T cells and DC to 
CMA resulted in a complete abrogation of PD-L1 and CD209 transfer. Of interest, 
inhibition of trogocytosis in CMA-pretreated T cells had no impact on the up-regulation of 
activation marker such as CD25 and CD137 (see Figure 30A). These results show that the 
inhibition of trogocytosis does not impair T-cell activation although pre-activation of T 
cells favours increased transfer capacity (see Figure 17). Moreover, degranulation marker 
CD107a, which is often used as cytotoxic marker for the degranulation of granzyme and 
perforin, was also up-regulated (Rubio, Stuge et al. 2003) showing that CD107a is not a 
selective marker for cytotoxicity of T cells (see Figure 30B).  
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Figure 29: Impairment of trogocytosis of membrane fragments, PD-L1 and CD209 by vATPase-
inhibitor Concancamycin A (CMA) pretreatment of T cells and mDC. CD8+ Mart-1-specific T cells 
and/or mDC were pretreated overnight with CMA which was washed out before co-culture. mDC were pulsed 
with Mart-1 peptide and labeled with PKH67. (A) After co-culture of 2h, uptake of membrane fragments, PD-
L1 and CD209 was analyzed by flow cytometry (black solid line). Negative or isotype controls are presented 
No CMA treatment
PKH67 PD-L1 CD209
CMA treatment of mDC
CMA treatment of CD8+ T 
cells
CMA treatment of CD8+ T 
cells and mDC
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as filled histograms. Histograms are gated on CD8+PKH67low lymphocytes. Shown is one representative of 
three independent experiments with similar results. (B) In bar graphs, MFI data of antigen-specific transfer 
was set to 100% as maximum transfer. Inhibited transfer of co-culture of mDC with CMA-pretreated T cells 
and no transfer are shown as percentage of maximum uptake of membrane fragments and PD-L1 of four 
independent experiments + SD (*** p<0.001, paired t test). 
 
 
 
Figure 30: T cell activation despite CMA pretreatment after co-culture with mDC. Mart-1 specific T 
cells with or without CMA pretreatment were co-cultured with Mart-1-pulsed, PKH67-labeled mDC. 
Expression of activation markers CD25 and CD137 after 22h (A) as well as of degranulation marker CD107a 
(black solid line) after 2h (B) was analyzed by flow cytometry. Isotype controls are presented as filled 
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histograms Dot Plots and histograms are gated on CD8+PKH67low lymphocytes. Shown is one representative 
of three independent experiments with similar results. 
 
 
3.9.6. Inhibition of the transfer by blocking of the intracellular protein 
transport  
Perturbation of the Golgi apparatus comes along with effects as blockade of secretion as 
well as disturbance of vesicular transport. Monensin is described as carboxylic ionophore 
binding Na+/H+, cations which are important in many physiologic processes (Dinter and 
Berger 1998). Monensin was added to the co-culture of Mart-1-specific CD8+ T cells and 
Mart-1-pulsed, PKH67-labeled mDC. Monensin treatment was observed to cause decreased 
uptake of membrane patches (MFI of 40.2 compared to 100.6 without inhibition) and 
CD209 (MFI of 54.5 compared to 113.0 without inhibition) (see Figure 31). 
 
Transfer
PKH67
Transfer with
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CD209
MFI= 100.6
MFI= 40.2 MFI= 54.5
MFI= 113.0
 
 
Figure 31: Blocking of intracellular protein transport by monensin impairs trogocytosis.  Mart-1-
specific T cells were co-cultured with Mart-1-pulsed, PKH67-labeled mDC with or without addition of 
Monensin, applied by 0.67µL/mL GolgiStop. After 2h, acquisition of PKH67 and CD209 was analyzed by 
flow cytometry (black solid line). Negative or isotype controls are presented as filled histograms. Histograms 
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are gated on CD8+PKH67low lymphocytes. Shown is one representative of three independent experiments with 
similar results.  
 
3.10. Functionality of transferred PD-L1 on T cells 
In order to investigate whether acquired PD-L1 on human CD8+ T cells is functionally 
active and inhibits PD-1 expressing neighboring T cells, the following set-up was generated 
as depicted in Figure 32. 
 
 
 
Figure 32: Experimental set-up. The graphic shows the procedure for functional analysis of acquired PD-
L1: T cells of a gp100-sepcific T cell clone were co-cultured either with gp100-pulsed mDC or anti-
CD3/CD28 beads for 2h. Then, CD3+CD8+ T cells were sorted out of both co-cultures, the one population 
showing a PD-L1+ (gp100(mDC)PD-L1acq+), the other population a PD-L1- (gp100(beads)PD-L1-) phenotype. 
These sorted T cells were pulsed with Mart-1 peptide. Next, either gp100(mDC)PD-L1acq+ or 
gp100(beads)PD-L1- sorted T cells were co-cultured with expanded, cytotoxic, Mart-1-specific T cells (CTL) 
1.Co-culture of gp100-specific T cells with a) gp100-pulsed PD-L1+ mDC
or b)  anti-CD3/CD28 beads
a) b)
2. Sorting of CD3+CD8+ T cells
PD-L1acq+ T cells PD-L1- T cells
3. Pulsing of sorted T cells with 
Mart-1 peptide
4. Co-culture of gp100-specific
a) PD-L1acq+ or b) PD-L1-
Mart-1-pulsed T cells
with PD-1 expressing 
Mart-1-specific CD8+ T cells
5. Analysis of apoptotic  
Mart-1-specific TM+ CD8+ T cells
via flow cytometry
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expressing PD-1. After 6h, apoptosis rate was analyzed by Annexin V and 7-AAD staining in CD3+CD8+ 
Mart-1 TM+ T cells via flow cytometry. 
 
 
First, a gp100-specific T-cell clone was stimulated with gp100 peptide-pulsed mDC (PD-
L1acq+) or with anti-CD3/CD28 beads (PD-L1-). Next, CD3+CD8+ cells were sorted and 
subsequently pulsed with Mart-1 peptide to ensure interaction with Mart-1-specific 
neighboring T cells. Expression of acquired PD-L1 on gp100-specific T cells remained 
stable during the experimental procedure (see Figure 33). Of note, PD-L1 was not up-
regulated on T cells after anti-CD3/CD28 bead stimulation. Next, sorted and Mart-1-pulsed 
gp100-specific T cells were used as APC and co-cultured with Mart-1-specific, PD-1 
expressing T cells (data not shown). Of importance, Annexin V and 7-AAD staining of PD-
1+, Mart-1-specific T cells that were co-cultured with PD-L1 acquiring gp100-specific T 
cells revealed an increase in apoptotic cells of 28% compared to 12% in the control setting 
(co-culture with PD-L1- gp100-specific T cells) (p=0.0239) (see Figure 34). To confirm 
these findings, a blocking anti-PD-L1 mAb was added to the co-culture resulting in a 
significant reduction of apoptosis to 15.3% (p=0.0214). Together, these data clearly 
emphasize that acquired PD-L1 on antigen-specific T cells is functionally and can interact 
with its receptor PD-1 on neighboring T cells to induce apoptosis. 
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Figure 33: PD-L1 maintenance of gp100(mDC)PD-L1acq+ T cells during experimental procedures. 
Gp100-specific CD8+ T-cell populations either stimulated with mDC or anti-CD3/CD28 beads were 
monitored for PD-L1 after stimulation, after cell sort and after antigen-pulsing (black solid line). Isotype 
controls are presented as filled histograms. Histograms are gated on CD8+ lymphocytes. Shown is one 
representative of three independent experiments. 
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Figure 34: PD-L1 triggering apoptosis in neighboring T cells. After 6h co-culture of Mart-1-specific CTL 
with either gp100 PD-L1acq+ T cells with or without anti-PD-L1 blocking antibody (αPD-L1), or gp100 PD-
L1- T cells, CD3+CD8+ Mart-1 TM+ CTL were analyzed for 7-AAD and Annexin V double positive cells. 
Shown are dot plots from one representative of three independent experiments with similar results. Bar graph 
shows the x-fold increase of percental apoptosis rate compared to unstimulated CD3+CD8+ Mart-1 TM+ CTL 
with data of three independent experiments + SD (* p<0.05 paired t test). 
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4. Discussion 
 
In this study, the acquisition of PD-L1 and CD209 by human CD8+ T cells from DC is 
demonstrated and characterized for the first time. Moreover, these data emphasize a 
potential new mechanism of immune regulation by acquisition of co-inhibitory molecules 
such as PD-L1 by CD8+ T cells from both DC and melanoma cells.  
 
Trogocytosis is described as intercellular transfer of membrane fragments. This study 
shows that human CD8+ T cells acquire both lipid components and proteins during this 
process. Although many fragments are acquired out of the plasma membrane, it is not a 
random transfer of molecules: mDC highly express CD80, CD83, CD86, PD-L1, CD209 as 
well as PD-L2, but antigen-specific CD8+ T cells only acquire PD-L1, CD209 as well as 
CD83 upon antigen-recognition on mDC. Of note, no increase of surface CD80 and CD86 
can be observed in our antigen-specific human model although trogocytosis of CD80 by 
murine T cells has been demonstrated in other reports (Sabzevari, Kantor et al. 2001; 
Mostbock, Catalfamo et al. 2007). Thus, a so far unknown mechanism on DC or T cells 
must determine which molecules are transferred and which are not. 
The structure of molecules and their anchorage in the plasma membrane may be one 
important feature for the exchange of molecules. Comparing the cytoplasmic parts of listed 
molecules, PD-L1, CD83, CD80, and CD86 are all described to have short cytoplasmic 
tails (Peach, Bajorath et al. 1995; Zhou and Tedder 1995; Keir, Butte et al. 2008). Just 
CD209 is reported to have an intracellular domain for signaling and to have internalization 
motifs. In the case of PD-L2, two forms are described to exist, namely one variant on the 
plasma surface and another located intracellular (He, Liu et al. 2004). However, the transfer 
of PD-L2 could not be detected at all. Despite a similar location and structure in the plasma 
membrane, PD-L1 is transferred very efficiently whereas no acquisition of CD80 and CD86 
is documented on antigen-specific T cells. This shows that the cytoplasmic tail is not 
critical for the outcome in trogocytosis. In regard to CD83, a soluble form was observed 
which is shed from the surface of CD83 expressing cells (Hock, Kato et al. 2001; 
Lechmann, Berchtold et al. 2002). Thus, the detected CD83 on the surface of CD8+ T cells 
may also result from the uptake of soluble CD83 and is not proved to be acquired by 
trogocytosis. In addition to these surface molecules, also cytoplasmic expressed GFP is 
transferred in detectable amounts in an antigen-specific manner from mDC onto T cells. 
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This is in accordance to the described transfer of intracellular protein H-Ras from B cells to 
human T and NK lymphocytes (Rechavi, Goldstein et al. 2007). Daubeuf et al. propose that 
proteins present in the internal leaflet exhibit a higher mobility than their external leaflet 
counter-parts and are therefore transferred more efficiently (Daubeuf, Aucher et al.). 
Putting the focus on the inner leaflet, it has been described that phosphatidylserine (PS) at 
the inner leaflet of the plasma-membrane of T cells is exposed to the outer cell upon 
activation showing the flexibility of the inner leaflet and its exposure to the outside 
(Fischer, Voelkl et al. 2006). Of note, blocking the PS exposure as well as the inhibition of 
trogocytosis is not accompanied by an impaired up-regulation of activation markers as 
shown in this study for reduced transfer of PD-L1 and CD209 by Concanamycin A or by 
fixation of APC. Interestingly, this PS exposure is happening very quickly providing 
similar kinetics as the transfer process and is probably engaged in the cell-to-cell contact 
formation. Thus, PS is proposed by Fischer et al. to contribute significantly to events at the 
IS. Moreover, a role of exposed PS was described in the adhesion and migration processes 
of murine CD4+ T cells (Elliott, Surprenant et al. 2005). Furthermore, PS-receptors may be 
important in the up-take of microvesicles (Miyanishi, Tada et al. 2007). Regarding the 
common features of these two antigen-triggered processes, PS exposure may also play a 
role in trogocytosis.   
Besides CD8+ T cells, CD4+ T cells as well as DN T cells acquire CD209 and membrane 
fragments to a similar extend after antigen-recognition. Human DN T cells have already 
been described by our group to acquire HLA molecules in an antigen-independent manner 
(Fischer, Voelkl et al. 2005). Moreover, the kinetics indicated that the mechanism of 
capture may be different, because of the increased amount of acquired molecules after 72 
hours whereas membrane fragments, PD-L1 and CD209 in the antigen-specific setting 
disappeared completely from the cell surface after this period of time. In contrast, the 
acquisition of allogeneic MHC molecules by murine DN T cells has been demonstrated to 
be antigen-specific showing similar kinetics as the acquisition of HLA molecules by human 
DN T cells. These data suggest that different mechanisms for a cell-to-cell contact 
dependent transfer do exist (Ford McIntyre, Young et al. 2008). Moreover, the different T-
cell subsets revealed a similar accessibility in the uptake of membrane fragments and 
CD209 in the case of antigen-specific acquisition whereas human DN T cells clearly 
acquired much more HLA molecules than CD8+ T cells in the case of antigen-independent 
transfer of HLA-A2. It has been shown for murine CD4+ and CD8+ T cells that they acquire 
similar amounts of surface molecules after antigen-recognition as this study observes for 
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human trogocytosis (Daubeuf, Aucher et al.). Taken together, antigen-specific trogocytosis 
does occur in different T-cell subsets to a similar extent, but antigen-specific and non-
specific transfer of surface molecules seem to underlie to different mechanisms. 
Immune cells are interacting and networking with each other. In recent studies many cells 
have been described to transfer molecules between different immune and/or target cells 
(LeMaoult, Caumartin et al. 2007; Quah, Barlow et al. 2008; Caumartin, Favier et al. 2007; 
Beum, Mack et al. 2008). However, CD8+ T cells acquire low amounts of membrane 
fragments from B cells, NK cells, and monocytes, but high amounts of membrane 
fragments from iDC and mDC. This is the first report comparing the efficiency of different 
donor cells to transfer molecules onto human T cells. This efficient trogocytosis process 
from DC may be due to the expression of co-stimulatory molecules. Moreover, iDC and 
mDC as professional APC present more pMHC complexes to T cells what also favors 
trogocytosis as described by Hudrisier et al. (Hudrisier, Riond et al. 2005). Of interest, 
membrane fragments and surface molecules PD-L1 and CD209 are even not equally 
acquired from iDC and mDC which may be connected to the higher expression of co-
stimulatory molecules on mDC than on iDC mediating a stronger interaction with T cells 
and therefore triggering trogocytosis. Of note, CD209 is expressed at similar levels on the 
surface of iDC and mDC but was hardly detectable on T cells after co-culture with iDC 
suggesting that the molecule densitiy on the surface is not crucial for the efficiency of 
trogocytosis. However, Hudrisier et al. have shown that levels of TCR engagement 
correlate with the proportion of antigenic complexes amongst the plasma membrane 
materials captured by CTL from target cells via trogocytosis (Hudrisier, Riond et al. 2005). 
Thereby, DC presenting more pMHC complexes trigger trogocytosis more efficiently than 
monocytes, B cells and NK cells. Conform to the hypothesis that co-stimulatory molecules 
are important for the efficiency of the transfer, trogocytosis from melanoma cells missing 
co-stimulatory molecules is weaker than this from mDC. Only low amounts of highly 
expressed MCSP and PD-L1 are transferred from melanoma cell lines onto antigen-specific 
T cells.  
TCR-dependency has been described as a trigger for the trogocytosis process (Huang, Yang 
et al. 1999; Hudrisier, Riond et al. 2001). In line with these reports, this study demonstrates 
that antigen-recognition by TCR is also essential for the transfer of PD-L1 and CD209 
surface molecules. Thereby, the enduring strong cell-to-cell interactions as well as changes 
in the membrane dynamics may play a role for antigen-dependent triggering of 
trogocytosis. Of note, PD-L1 is also described to be expressed upon activation on human T 
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cells but expression of mRNA and translation into protein take much longer than PD-L1 
acquisition from antigen-presenting cells via trogocytosis. Trogocytosis has been described 
as a phenomenon of very fast exchange of cell components compared to exosomes and 
nanotubes which correlates with the kinetics of the uptake of membrane patches, PD-L1, 
and CD209 in this study (Davis 2007). Moreover, surface-PD-L1 was neither observed 
after co-culture with antigen-pulsed PD-L1- T2 cells nor after stimulation with anti-
CD3/CD28 beads demonstrating that PD-L1 is actually not endogenously up-regulated on 
T cells after antigen-specific activation with APC in this time frame. In summary, 
trogocytosis renders CD8+ T cells immediately but just temporary to a cell with newly 
acquired features as kinetics show that acquired membrane patches and surface molecules 
completely disappear within 72 hours.  
Cell-to-cell contact is one important requirement for the transfer of membrane fragments 
and surface molecules such as PD-L1 and CD209 onto T cells what is also reported for the 
uptake of HLA-G by human T cells (LeMaoult, Caumartin et al. 2007). Thus, trogocytosis 
is mediated by uptake of floating cell fragments after lysis of target cells but a targeted 
transfer triggered by antigen-recognition. Together, PD-L1 and CD209 transfer matches the 
characteristics of trogocytosis: the transfer is 1) very fast, 2) requires cell-to-cell contact, 
and 3) is triggered by antigen-recognition. Nevertheless, despite the transwell system 
indicating a cell-to-cell contact dependent mechanism, the involvement of membrane 
vesicles can not be completely excluded since vesicles have also been described to be 
directly transferred upon close cell-to-cell contact (Muratori, Cavallin et al. 2009). Of note, 
bystander T cells are not triggered by neighboring T cells to acquire surface molecules such 
as PD-L1 and CD209 demonstrating that trogocytosis is a targeted process that is not cross-
transferred to non-reactive bystander T cells. Furthermore, these data emphasize that T cells 
do not capture exosomes released by activated DC. Therefore, trogocytosis can be defined 
as selective process to orchestrate immune responses supporting the hypothesis of HLA-
matched trogocytosis by Machlenkin et al. (Machlenkin, Uzana et al. 2008).  
The mechanisms triggering antigen-dependent trogocytosis on T cells are unknown. The 
immunological synapse is an important feature in T-cell activation. Candidate molecules 
are either adhesion molecules that are essential for close interaction between effector T 
cells and target cells or co-receptors as well as co-stimulatory molecules in triggering the 
TCR signal cascade. Blocking of the CD8 co-receptor actually impaired the transfer of 
membrane fragments and CD209. This observation confirms the study of Hudrisier et al. 
showing an impaired transfer of membrane fragments after blocking of CD8 on murine 
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CD8+ T cells (Hudrisier, Riond et al. 2001). Blocking adhesion molecules as CD209, 
ICAM-1, and ICAM-2 as well as co-stimulatory molecules as CD80 and CD86, but also 
blocking of the target molecules PD-L1 and CD209 had no effect on the trogocytosis 
process. This may explained by the fact that one adhesion molecule or co-stimulatory 
molecule can be replaced by others, resulting in sustained stimulation and trogocytosis. In 
contrast, binding of the CD8 co-receptor is crucial for T-cell activation and for 
trogocytosis.  
Besides this, the arrangement in and around the immunological synapse (IS) is dependent 
on membrane organization and may be critical for the determination which molecules are 
transferred or not. However, the formation of the IS endures about 30 minutes when 
trogocytosis is already going on and therefore the organization of the molecules in the 
immunological synapse does not seem to play a role for the choice of acquired molecules 
(Anton van der Merwe, Davis et al. 2000). As far as molecules belonging to both the 
cSMAC and the outer region of the IS are transferred, e.g. pMHC complexes and PD-L1, 
the placing in or outside the IS can also not explain which molecules are preferentially 
acquired by T cells. Moreover, pretreatment of T cells with blebbistatin was described to 
lead to a more peripheral distribution of these interactions because of an impaired transport 
of the molecule complexes toward the centre to arrange an IS (Ilani, Vasiliver-Shamis et al. 
2009). This arrangement is also not critical to trigger trogocytosis because T cells 
pretreated with blebbistatin acquire similar amounts of membrane fragments and PD-L1 as 
untreated T cells. This demonstrates that the localization of molecules is not relevant for the 
acquisition from the target cell. Having a closer look onto T cell activation, the src kinases 
are important factors downstream the TCR signaling cascade (Salmond, Filby et al. 2009). 
Although the blocking of scr kinases was described by Hudrisier et al. to impair the uptake 
of membrane fragments, this could not be confirmed for the acquisition of membrane 
fragments, PD-L1 and CD209 by highly affine antigen-specific T cells in this study 
proposing that the first steps of T-cell activation as antigen-recognition and ligation of co-
receptors are the more critical items in triggering trogocytosis (Hudrisier, Riond et al. 
2001).    
In addition, this study demonstrates that both, inhibition of vATPases and fixation of APC, 
strongly impair trogocytosis suggesting that the trogocytosis process is controlled by 
membrane dynamics as it was also shown by the dependence on an active actin 
cytoskeleton for trogocytosis by T cells (Hudrisier, Aucher et al. 2007). vATPases are 
desribed to play a role in endo-, exocytosis, and membrane trafficking (reviewed in 
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(Marshansky and Futai 2008)). Of interest, impairment of vATPases in mDC has only a 
minor impact on the acquisition of cell components from mDC by T cells whereas 
impairment of vATPases in T cells results in a very strong inhibition of the trogocytosis 
process. These data indicate that vATPases play a role in the integration of disrupted 
molecules from neighboring cells into the plasma-membrane. While the transfer process is 
abolished when vATPases are impaired, T cells became nevertheless activated measured by 
up-regulation of CD25 and CD137. These results clearly demonstrate that activation is not 
linked to trogocytosis. Furthermore, CD107a, an antigen described as T-cell degranulation 
marker, is up-regulated despite inhibited perforin and granzyme B secretion (Togashi, 
Kataoka et al. 1997; Betts, Brenchley et al. 2003). Moreover, fixation of mDC completely 
abrogates the transfer process suggesting that the surface of DC must not be static to enable 
acquisition by T cells but has to be dymamic. Up-regulation of activation markers such as 
CD25 and CD137 on T cells demonstrates that pMHC-complexes are still functional 
despite fixation of APC. Although pre-activation triggers trogocytosis as it is also described 
by LeMaoult et al., impairment of trogocytosis does not influence the up-regulation of 
activation markes on T cells proposing that trogocytosis does not play a role in the cascade 
of events of full T-cell stimulation (LeMaoult, Caumartin et al. 2007). 
Intracellular trafficking inside the cell which acquired the molecules may be a critical point 
in trogocytosis as the transfer of membrane fragments and surface molecules is impaired 
after Monensin treatment. monensin is described to inhibit vesicle trafficking by lysosomes, 
to disturb the golgi apparatus and to inhibit the recycling out of early endosomes (Basu, 
Goldstein et al. 1981; Tartakoff 1983; Muro, Mateescu et al. 2006). Of interest, molecules 
are recycled from early endosomes, so-called recycling endosomes, to be presented again 
on the plasma membrane. One possible mechanism for re-presentation on the surface again 
is explained via a so-called kiss-and-run mechanism (Lencer and Blumberg 2005). 
Eventually, acquired molecules are not integrated directly from the outside into the plasma-
membrane but after recycling in early endosomes to be integrated functionally active 
(Jovic, Sharma et al. 2010). The kinetics of the recycling process and functionally 
presentation of molecules on the surface is important to link it to trogocytosis. However, 
the processing by recycling endosomes could explain the functionally active integration of 
acquired molecules into the plasma membrane. 
For a broader understanding of trogocytosis, further investigations could enlighten the role 
of the flipping events at the plasma membrane as well as of recycling endosomes in the 
transfer process what may elucidate the mechanism of this phenomenon. Binding studies 
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could prove the functionality of acquired CD209 showing if this molecule can still enable 
the contact formation with other T cells after the transfer process. Furthermore, it could be 
tested if different effector and memory T-cell subsets show a different behavior in the 
transfer of surface molecules to see whether T cells acquire molecules at a special state of 
differentiation. 
 
Compared to other reports on trogocytosis focusing mostly on the transfer of stimulatory 
molecules, this is the first report of acquisition of a widespread inhibitory molecule. 
Although HLA-G was described to render NK and T cells temporary to regulatory cells 
after acquisition of this non-classical MHC class I molecule, HLA-G is characterized by 
limited polymorphism and a restricted expression to immuno-privileged sites such as fetal-
maternal interface (Caumartin, Favier et al. 2007; LeMaoult, Caumartin et al. 2007; 
Carosella, Moreau et al. 2003). This study focuses on the transfer of PD-L1 whose receptor 
PD-1 is expressed on a wide variety of human immune cells indicating an extensive 
regulatory role of PD-L1 acquisition. Thus, interaction of T cells that have acquired PD-L1, 
with other PD-1 expressing cells as B cells and macrophages could further modulate 
immune responses (Keir, Butte et al. 2008). As far as PD-L1 is not only expressed by 
hematopoietic cells, also the interaction of T cells with non-hematopoietic PD-L1 
expressing cells should be examined, e.g. vascular endothelial cells, epithelia, and cells at 
immune privileged sites including trophoblasts in the placenta and retinal pigment 
epithelial cells or neurons in the eye. At these anatomic sites it remains unclear whether T 
cells can also acquire molecules such as PD-L1 and spread their function to the 
environment (Francisco, Sage et al.). Besides this, the parallel transfer of CD209 which is 
exclusively expressed on DC is also described for the first time in this study. CD209 
functions as adhesion molecule initiating first interaction between DC and T cells via 
binding of ICAM-3 as reviewed in Zhou, Chen et al. 2006, hence acquired CD209 on T 
cells may temporary support the interaction and cross-talk with neighboring T cells. 
Of importance, this study shows that acquired PD-L1 is able to trigger apoptosis in 
neighboring PD-1 expressing T cells proposing an immune-regulatory function by silencing 
T-cell responses after antigen-clearance. Regarding the functional outcome of surface PD-
L1, the higher expression of both, PD-L1 and especially of co-stimulatory molecules on 
mDC, keeps the balance in favor of priming and boosting T cells. A shift causing 
imbalance with a predominant PD-L1 expression compared to expression of costimulatory 
molecules on mDC results in an overweighting inhibitory signaling of PD-L1 as described 
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in chronic infections (Shen, Chen et al.). In case of PD-L1 acquisition by T cells, T cells 
lack co-stimulatory molecules causing the outbalanced signaling of PD-L1 which results in 
apoptosis of neighboring T cells. Thereby, an overshooting immune reaction could be 
avoided. PD-1 signaling is described to result in either anergy or T-cell deletion depending 
on the amount of antigen-level whereat low antigen-levels cause deletion and high antigen-
levels end up in anergy (Goldberg, Maris et al. 2007; Tsushima, Yao et al. 2007; Parish and 
Kaech 2009).  
Trogocytosis of pMHC complexes was described in mice and humans (Huang, Yang et al. 
1999; Tsang, Chai et al. 2003; Fischer, Voelkl et al. 2005). Thus T cells presenting acquired 
pMHC-complexes besides adhesion molecule CD209 and inhibitory PD-L1 to neighboring 
T cells trigger apoptosis because of the low antigen-amounts after clearance of antigen-
presenting DC and/or infected cells and can also be killed via fratricide as it was described 
for T cells acquiring pMHC complexes (Huang, Yang et al. 1999). The acquisition of PD-
L1 by tumor infiltrating T cells may spread the inhibitory function to the tumor 
environment and may therefore serve as a tumor immune escape mechanism. Many 
melanoma cell lines are described to up-regulate PD-L1 upon IFN-γ exposition hence in the 
case of an inflammatory immune response (He, Wang et al. 2005).  
In chronic infections, acquired PD-L1 may contribute to exhaustion of T-cell responses 
because of the long lasting pathogen burden when T cells are already silenced before the 
pathogen is cleared. Increased PD-1 expression levels on T cells are described for chronic 
infections as HBV promoting the exhaustion state of T cells which may end up in deletion 
of T cells triggered by acquired PD-L1. However, T cells with acquired PD-L1 may also 
interact with PD-1 expressing B cells, macrophages, or DC as mentioned above. Of 
interest, PD-1 signaling can not only silence TCR signaling but also BCR signaling (Agata, 
Kawasaki et al. 1996). Moreover, PD-1 signaling can inhibit DC and macrophage responses 
to microbes and is described to be up-regulated on macrophages and monocytes in case of 
sepsis pointing out the diversity of possible interactions of T cells after PD-L1 acquisition 
(Huang, Venet et al. 2009; Yao, Wang et al. 2009). 
Considering the in vivo relevance, human plasmacytoid DC (PDC) are described to express 
high levels of PD-L1 in HIV infection and generally upon activation (Francisco, Sage et al. 
; Cavaleiro, Baptista et al. 2009). Moreover, accumulation of PDC in skin is shown for 
infection with either human papilloma virus or human herpes simplex virus where T cells 
can interact with those PDC and acquire PD-L1 (Sozzani, Vermi et al.). Furthermore, Treg-
conditioned myeloid DC (MDC) cross-talk with T cells in the periphery where T cells also 
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could grab PD-L1 and spread a regulatory effect (Amarnath, Costanzo et al. 2010). Thus, T 
cells have the chance in the periphery to acquire molecules from DC as shown in this study 
in vitro and can subsequently interact with immune cells in the environment. The relevance 
of trogocytosis in lymph nodes remains to be discussed as T cells have to home to the site 
of infection after priming. This migration probably takes longer than acquired PD-L1 is 
present on the surface after trogocytosis so that no T cells are silenced at the primary site of 
infection after activation of naïve T cells in lymph nodes. Aside from this, the co-
stimulatory signals in the lymph nodes should be predominant and strong enough to 
overcome the inhibitory signal of acquired PD-L1.  
Looking from bench to bedside, this study emphasizes that transfer of PD-L1 could have a 
major impact on the down-regulation of immune-responses as displayed by the induction of 
apoptosis and could also play a role in the failure of immune responses in chronic diseases 
and tumors. The acquisition of PD-L1 in ex vivo expanded T cells should be considered in 
studies for adoptive cell transfer therapies, thus the administration of T cells should be 
carried out at the end of a stimulation cycle to avoid the transfer of highly PD-L1+ T cells 
as it is already described that the blockade of PD-L1 augments human tumor-specific T cell 
responses (Blank, Kuball et al. 2006). Zhou et al. recently showed that interaction between 
PD-1 and PD-L1 can facilitate Treg-induced suppression of exogenously administered CTL 
propagated from non-tumor bearing mice and can dampen the anti-tumor immune 
responses in advanced AML disease (Zhou, Munger et al.). Not only in tumors, but also in 
the treatment of chronic infections as HBV where specific T cells show an increased PD-1 
expression, blocking PD-L1 can cause restoration of proliferation and cytokine production 
ex vivo (Fisicaro, Valdatta et al.). Besides the adoptive cell therapy with ex vivo expanded T 
cells, administration of PD-L1 expressing DC could spread PD-L1 by trogocytosis in the 
tumor patients or patients with chronic infections. In conclusion, a combinatorial treatment 
of both, transfer of immune cells and administration of PD-1 blocking antibodie, may be an 
interesting strategy to avoid widespread inhibitory PD-L1 effects that can also be mediated 
by trogocytosis.  
PD-L1 not only plays a role in cancer and chronic infections but also in the tolerance 
induction in autoimmunity. Thus trogocytosis of PD-L1 may act as a further regulatory 
mechanism for the induction or maintenance of tolerance (Francisco, Sage et al.). On the 
one hand, PD-L1 is described as an important factor for the induction of iTregs (Francisco, 
Salinas et al. 2009). On the other hand, adoptive transfer studies have identified critical 
functions for PD-L1 on transferred T cells mediating protective effects in the recipient 
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animal: Latchman et al. has shown in an EAE model that PD-L1 on T cells could limit 
responses of self-reactive CD4+ T cells (Latchman, Liang et al. 2004). The critical role for 
the maintenance of tolerance in the intestine by the PD-1/PD-L1 interaction was 
demonstrated in a mouse model by Reynoso et al. (Reynoso, Elpek et al. 2009). Missing of 
PD-1/PD-L1 signaling resulted in severe enteric autoimmunity. Thus, the transfer of PD-L1 
may also play a role in the maintenance of tolerance and may be crucial in the depression of 
self-reactive T cells. Taken together, trogocytosis of PD-L1 may be involved in the balance 
regulation between immunity and tolerance as proposed in Figure 35. 
 
PD-L1
mDC
T cell
TCR
PD-1
TCR
IMMUNITY
TOLERANCE• deletion of Teffector cells
• anergy of T effector cells • deletion of self-reactive T cells
• induction of regulatory T cells  
 
Figure 35: Potential consequences of acquired PD-L1.  Acquired PD-L1 may result in inhibition of effector 
T-cell responses or may induce T-cell tolerance. 
 
In summary, PD-L1 is a molecule with widespread functions in case of tolerance and 
immunity. It plays different roles in health, in chronic infections and tumors as well as in 
autoimmunity. This should emphasize the importance of this study about PD-L1 which is 
spread between cells via trogocytosis. To analyze the role of acquired PD-L1 in vivo, either 
an adoptive transfer mouse model in a tumor or chronic infection setting may give 
important insights into the physiologic role of transferred PD-L1. Tracking trogocytosis in 
a humanized mouse model by a GFP-linked PD-L1 construct may give further hints about 
the in vivo process. As far as PD-L1 can be both up-regulated upon stimulation and 
acquired by T cells via trogocytosis, PD-L1 could be blocked in the expansion of antigen-
specific T cells to examine if there is a better expansion and if there are less anergic cells 
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resulting in better effector functions of expanded T cells as cytokine release and 
cytotoxicity.  
Of interest, trogocytosis is described as a phenomenon carried out by many immune cells 
but also other kinds of cells. Such a widespread phenomenon is very probable to have an 
important role in vivo showing a high flexibility of the whole system and the possibility to 
confer temporary features between diverse cell populations. A profound understanding of 
the mechanism of trogocytosis and the physiologic relevance in immune-regulation may 
have important implications for novel immunotherapeutic strategies. 
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5. Summary 
 
Specific T-cell responses are initiated by TCR recognition of pMHC-complexes on APC. 
Upon specific interaction of T cells with APC, T cells capture membrane fragments and 
surface molecules in a process termed trogocytosis. Exchange of membrane 
molecules/antigens between immune cells has been observed for a long time, but the 
mechanisms and functional consequences of these transfers remain uncertain. This study 
demonstrates that human antigen-specific CD8+ T cells acquire the co-inhibitory molecule 
PD-L1 from mature monocyte-derived DC and tumor cells as well as the DC-specific 
adhesion molecule CD209 in an antigen-specific manner. Furthermore, also cytosolic 
proteins are transferred after antigen-recognition. Of note, not only CD8+ T cells can 
acquire membrane fragments and surface molecules but also CD4+ and DN T cells. 
Antigen-pulsed iDC are less effective in transferring surface molecules such as PD-L1 and 
CD209 onto CD8+ T cells after antigen-specific recognition even though CD209 is 
expressed at similar levels on iDC and mDC. However, T cells interacting with monocytes, 
NK cells or B cells acquire only low amounts of membrane fragments. The recognition of 
melanoma cell lines gives rise to an efficient transfer of membrane molecules but also PD-
L1 and MCSP are transferred onto T cells to a certain extend. The kinetics of the 
acquisition of membrane fragments, PD-L1 and CD209 reveal a maximal exposition of 
acquired cell components after about two hours after co-incubation with antigen-pulsed 
APC, being detectable up to 72 hours. Using a transwell system this study shows that the 
acquisition of membrane patches, PD-L1 and CD209 requires cell-to-cell contact. 
Furthermore, these cell components cannot be acquired by T cells from a lysate of mDC. 
Of importance, a parallel transfer onto antigen-unspecific bystander T cells can be 
excluded. Moreover, fixation of DC with glutaraldehyde completely abrogates the 
acquisition of PD-L1 and CD209 on T cells suggesting that an active interaction between 
APC and T cells is required for trogocytosis. The co-receptor CD8 seems to play an 
important role in this trogocytosis process since blockade of this co-receptor impairs the 
transfer of membrane fragments as well as of surface molecules. The formation of cSMAC 
and pSMAC impaired by the inhibition of Myosin IIA, is not critical for triggering 
trogocytosis. Furthermore, blocking of the src kinase lck has no impact on the transfer of 
membrane fragments, PD-L1, and CD209 excluding a crucial role of the downstream TCR 
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signal cascade in trogocytosis. The transfer process can be blocked after pretreatment of T 
cells with concanamycin A, a specific inhibitor of vacuolar ATPases, playing an important 
role in endo- and exocytosis, in the acidification of intracellular vesicles and in membrane 
trafficking. Monensin which is described to inhibit intracellular vesicle trafficking, to 
disturb the golgi apparatus as well as to inhibit the recycling out of early endosomes, is also 
capable of impairing trogocytosis, suggesting that intracellular vesicles may be of relevance 
for the transfer process. Moreover, an endogenous up-regulation of PD-L1 can be excluded 
as T-cell stimulation by antigen-pulsed PD-L1- T2 cells or by anti-CD3/CD28 beads does 
not result in surface expression of PD-L1. Of importance, CD8+ T cells which acquired PD-
L1 complexes are able to induce apoptosis in neighboring PD-1 expressing CD8+ T cells 
that can be completely blocked by an anti-PD-L1 antibody. In summary this study 
demonstrates for the first time new aspects in the mechanistic regulation of trogocytosis 
and shows that human antigen-specific CD8+ T cells take up functionally active PD-L1 
from APC in an antigen-specific manner triggering apoptosis of PD-1 expressing T cells. 
The transfer of functionally active co-inhibitory molecules from APC onto human CD8+ T 
cells may serve to limit clonal expansion of antigen-specific T-cell responses and to 
maintain tolerance by elimination of self-reactive T cells, but may also play a major role for 
T-cell exhaustion in chronic infection and tumor immunosurveillance. 
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Zusammenfassung  
 
 
Spezifische T-Zell-Antworten werden über die Erkennung von Peptid-MHC-Komplexen 
auf Antigen-präsentierenden Zellen (APC) durch T-Zell-Rezeptoren (TCR) initiiert. Nach 
antigen-spezifischer Interaktion von T Zellen mit APC können T Zellen sowohl 
Membranfragmente als auch Oberflächenmoleküle von APC akquirieren, ein Vorgang, der 
als Trogozytose definiert wird. Der Austausch von Membranmolekülen und –antigenen 
wurde schon vor langer Zeit beschrieben. Die zugrunde liegenden Mechanismen sowie 
funktionelle Konsequenzen dieser Transfervorgänge bleiben bisher jedoch ungeklärt. Die 
Untersuchungen der vorliegenden Arbeit zeigen, dass humane antigen-spezifische CD8+ T 
Zellen sowohl koinhibitorische PD-L1 Moleküle von reifen dendritischen Zellen (mDC) 
und auch Tumorzellen akquirieren können, aber auch dass das DC-spezifische Molekül 
CD209 bei der antigen-spezifischen Interaktion von T Zellen aufgenommen wird. Des 
Weiteren werden auch zytosolisch vorliegende Proteine nach Antigenerkennung auf die T 
Zelle übertragen. Bemerkenswerter Weise können neben den CD8+ T Zellen auch CD4+ 
und DN T Zellen Membranfragmente und Oberflächenmoleküle akquirieren. Antigen-
beladene unreife DC (iDC) sind allerdings weniger effizient bei der Übertragung von den 
Oberflächenmolekülen PD-L1 und CD209 nach Antigen-Erkennung auf CD8+ T Zellen als 
mDC, obwohl auf iDC und mDC eine vergleichbare CD209 Expression vorliegt. T Zellen, 
die dagegen mit Monozyten, NK Zellen oder B Zellen interagieren, akquirieren nur geringe 
Mengen an Membranfragmenten. Die Erkennung von Melanomzelllinien führt ebenfalls zu 
einer effizienten, antigen-spezifischen Übertragung von Membranfragmenten, aber auch 
PD-L1 und das Melanomantigen MCSP werden in detektierbareren Mengen auf T Zellen 
übertragen. Als ein limitierender Faktor ist die begrenzte Aufnahme von Zellkomponenten 
bei einer überwiegenden Anzahl an APC im Vergleich zu T Zellen zu nennen: ab einem 
gewissen Verhältnis von Zielzellen zu Effektorzellen erreicht der Transfervorgang eine 
Sättigung und es können nicht noch mehr Membranfragmente oder Oberflächenmoleküle 
aufgenommen werden. Die Kinetik der Übertragung von Membranfragmenten, PD-L1 und 
CD209 zeigt, dass nach einer zweistündigen Kokultur von T Zellen mit APC die maximale 
Menge an transferierten Zellkomponenten auf der T Zelle vorliegt. Diese auf der 
Zelloberfläche aufgenommenen Membranfragmente und –moleküle können jedoch bis zu 
72 Stunden detektiert werden. In dieser Arbeit konnte außerdem mittels eines sogenannten 
Transwell-Systems gezeigt werden, dass die Übertragung von Membranfragmenten, PD-L1 
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und CD209 ein Zell-Zell-Kontakt abhängiger Prozess ist. Außerdem können diese 
Zellkomponenten nicht aus einem Pool von lysierten, antigen-beladenen mDC von T Zellen 
aufgenommen werden. Des Weiteren kann eine antigen-unspezifische Übertragung auf 
Bystander T Zellen ausgeschlossen werden. Die Fixierung der mDC mit einer 
Glutaraldehydlösung kann außerdem die Übertragung von PD-L1 und CD209 komplett 
unterbinden, was darauf hinweist, dass eine dynamische Interaktion zwischen T Zellen und 
APC beim Trogozytoseprozess vorausgesetzt werden muss. Der CD8 Korezeptor scheint 
eine wichtige Rolle bei der Trogozytose zu spielen, da dessen Blockade eine 
Beeinträchtigung der Übertragung von Membranfragmenten und Oberflächenmolekülen 
zur Folge hat. Es wurde beschrieben, dass die Inhibition von Myosin IIA die Bildung von 
cSMAC und pSMAC negativ beeinflusst, was jedoch nicht entscheidend für den Verlauf 
der Trogozytose zu sein scheint. Außerdem übt auch die Blockade der Src-Kinase Lck, die 
eine Rolle in der TCR-Signalkaskade spielt, keinen inhibitorischen Effekt auf die 
Übertragung von Membranefragmenten, PD-L1 und CD209 aus, was eine entscheidende 
Rolle in der TCR Signalkaskade im Ablauf der Trogozytose ausschließt. Dahingegen hat 
die Inhibierung von vATPasen, die eine wichtige Rolle bei sowohl bei Endo- und 
Exozytosevorgängen, bei der Ansäuerung von intrazellulären Vesikeln als auch in 
Membrandynamik spielen, durch die Vorbehandlung der T Zellen mit Concanamycin A 
einen stark beeinträchtigenden Effekt auf die Übertragung von Zellkomponenten per 
Trogozytose. Auch Monensin, welches zur Beeinträchtigung des intrazellulären 
Vesikelverkehrs führt, die Prozesse am Golgi Apparat stört als auch das Recycling aus 
frühen Endosomen inhibiert, reduziert den Transfer von Membranfragmenten und 
Oberflächenmolekülen. Eine endogene Hochregulation und Expression von PD-L1 kann 
ausgeschlossen werden, da T Zellen sowohl nach Stimulation mit antigen-beladenen, PD-
L1- T2 Zellen als auch mit anti-CD3/CD28 Beads kein PD-L1 auf der T-Zelloberfläche 
exprimieren. Bemerkenswerterweise können CD8+ T Zellen, welche das PD-L1 akquiriert 
haben, in benachbarten PD-1 exprimierenden T Zellen Apoptose auslösen. Dieser Effekt 
kann komplett durch Zugabe eines PD-L1 blockierenden Antikörpers verhindert werden. 
Zusammengefasst beschreibt die vorliegende Arbeit neue mechanistische Aspekte der 
Trogozytose beschreibt  sowie die Übertragung von funktionell aktivem PD-L1 von APC 
auf humane CD8+ T Zellen, welches in PD-1 exprimierenden T Zellen Apoptose auslösen 
kann. Der Transfer von funktionell aktiven koinhibitorischen Molekülen von APC auf 
humane CD8+ T Zellen könnte dazu dienen, die klonale Expansion von antigen-
spezifischen T-Zellantworten zu limitieren sowie durch Eliminierung von selbst-reaktiven 
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T Zellen Toleranz aufrecht zu erhalten, könnte aber auch eine tragende Rolle bei der 
funktionalen Erschöpfung von T Zellen bei chronischen Infektionen und bei der Tumor-
Immunüberwachung spielen. 
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6. Abbreviations 
 
 
7-AAD 7-Aminoactinomycin 
ADCC Antibody dependent cell cytotoxicity 
AICD Activation induced cell death 
APC Allophycocyanin 
APC Antigen presenting cells 
ATP Adenosine triphosphate 
β2m β-2 microglubulin 
BCR B cell receptor 
CD Cluster of differentiation 
CLL Chronic lymphocytic leukemia 
CMA Concanamycin A 
CMV Cytomegalo-Virus 
cSMAC Central supramolecular activation cluster 
CTL Cytotoxic T lymphocyte  
CTLA-4 Cytotoxic T-lymphocyte-associated antigen 4; CD154  
DC Dendritic cells 
DC-SIGN DC-specific ICAM-3 grabbing non-integrin; CD209 
DMSO Dimethyl sulfoxide 
DN CD4- CD8- double-negative 
DNA Deoxyribonucleic acid 
EBV Epstein-Barr Virus 
EDTA Ethylenediaminetetraacetic acid 
FACS Fluorescence activated cell sorter 
FasL Fas-Ligand  
FcR  Fc receptor  
FCS Fetal calf serum 
FITC Fluorescein-Isothiocyanat 
Foxp3 Forkhead box P3 
FSC Forward scatter 
GFP Green fluorescent protein 
GM-CSF Granulocyte macrophage colony-stimulating factor 
GVHD Graft-versus-host disease;  
h Hours 
HBV Hepatitis B Virus 
HIV Human immunedeficiency virus 
HLA Human leukocyte antigen 
HSA Human serum albumin 
ICAM Intercellular adhesion molecule 
ICOS Inducible co-stimulator 
IFN-γ Interferon-γ 
IgG Immunglobulin G 
IL Interleukin 
ITAM Immunoreceptor tyrosine-based activation motifs 
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ITIM Immunoreceptor tyrosine-based inhibition motifs 
LAG-3 Lymphocyte activation gene-3 
LFA-1 Leukocyte function-associated antigen-1  
MCSP Melanoma-associated chondroitin sulfate proteoglycan 
MDR Multi-drug resistance 
MHC  Major histocompabitility complex 
MHC I MHC-class I complex 
MFI Mean fluorescence intensity 
MLR mixed-lymphocyte-reaction 
Melan-A MART-1; self-antigen on melanocytes which is 
overexpressed on melanoma cells 
MNC Mononuclear cells 
MS Multiple sclerosis 
NK cells Natural killer cells 
PAMP Pathogen-associated molecular patterns 
PBMC Peripheral blood-mononuclear cells 
PBS Phosphate buffered saline 
PD-1 Programmed-death 1; member of the B7-CD28 family 
PD-L1 Programmed death-ligand 1 
PE Phycoerythrin  
PerCP Peridinin-chlorophyll-proteine complex  
PFA Paraformaldehyde 
PGE2 Prostaglandin E2 
PHA Phytohemagglutinin 
pMHC Peptide-MHC complex 
PPR Pathogen pattern receptor 
PS Phosphatidylserine 
pSMAC Peripheral supramolecular activation cluster 
RNA Ribonucleic acid 
RT Room temperature 
RTX Rituximab 
SD Standard deviation 
SSC Side scatter 
TAA Tumor associated antigen 
TAP transporter associated with antigen-processing  
TCGF T-cell growth factor 
TCR T-cell receptor 
Teff Effector T cells 
TGF-β Transforming-growth-factor-β  
Th Helper T cells 
TIL Tumor infiltrating lymphocytes 
TLR Toll-like receptor 
TNF Tumor necrosis factor 
TNT Tunneling nanotubes 
TM MHC-Tetramer 
TRAIL TNF-related apoptosis inducing ligand 
Treg Regulatory T cells 
vATPases Vacuolar ATPases 
VEGF Vascular endothelial growth factor 
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